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ABSTRACT

In this dissertation, ultrasonication assisted Layer-by-Layer (LbL) technology for the
preparation o f multifunctional poorly water-soluble anticancer drug nanoparticles, paclitaxel
and lapatinib, has been developed. Many FDA approved drugs are very low soluble in water;
therefore, it is very difficult to load and control their release and targeting efficiently, which
greatly confines their application. The development o f this method will pave the way for the
development and application o f those low soluble anticancer drugs.
In the first part o f this dissertation, the first approach for powerful ultrasonication, the
top-down approach (sonicating bulk drug crystals in polyelectrolyte solution), was
successfully applied for the preparation o f the nanoparticles o f paclitaxel. For this approach,
a 200 nm diameter was a kind o f “magic” barrier for colloidal particles prepared. This
diameter barrier may be related to the nucleation size o f the solvent vapor microbubbles.
Consequently, agents enhancing bubbling formation (such as NH 4 HCO 3 ) were applied to
decrease paclitaxel colloid particles to 100-120 nm. Those paclitaxel nanoparticles were
Layer-by-Layer coated with a 10-20 nm polycation/polyanion shell to provide aqueous
colloidal stability and slower particle dissolution. However, a large obstacle o f these
powerful ultrasonication methods was a necessity o f long ca 45 minutes high power
ultrasonication which resulted in TiCL contamination from titanium electrode. The small
amount o f TiCL contamination from ultrasonication did negatively affect the in vivo testing o f

this system in mice, and had to be removed before low toxicity o f the Layer-by-Layer coated
pacclitaxel nanoparticles were observed.
In the second part o f the dissertation, the second approach for sonication, the bottom-up
approach (sonicating drug in a water-miscible organic solvent followed by slow water
add-in) was successfully applied for the preparation o f the nanoparticles o f lapatinib and
paclitaxel with less powerful sonication. By using polymeric excipients combined with
non-ionic and anionic surfactants along with regular sonication, the prepared particle sizes
was uniform at around 140-150 nm. Less sonication time (ca 15 minutes) and lower
sonication power avoided TiCL contamination. The amphiphiles attached to the hydrophobic
nanoparticles and served as anchors for LbL shell. The inner LbL layers and surfactants
minimized the surface free energy, thereby preventing crystal form changes and nanoparticles
coalescence, while the outermost layers enhanced colloidal stability.
In the third part o f the dissertation, LbL shells with PEGylation (using a block
copolymer o f poly-L-lysine (PLL) and PEG) for lapatinib were developed for enhanced
colloidal stability in high molarity PBS buffer.
In the above proposed paclitaxel and lapatinib formulation, we obtained 150-200 nm
with high drug content o f 80-90% due to very thin capsule walls (ca 10 nm). The drug release
time from the LbL capsules was found to be between 10 and 20 hours depending on the shell
thickness. Washless Layer-by-Layer assembly was used: 1) addition o f polycation in the
amount that is enough to reverse surface charge of the dispersion to a high positive (+30 mV)
value; 2 ) addition of polyanion in the amount that is enough to reverse surface charge o f the
dispersion to a high negative (-30 mV) value. No intermediate washing o f nanoparticles was
done until the shell was complete. The washless method had the advantage o f time and
energy saving, preservation o f the sample structure and no losses o f sample.

In the last part o f the dissertation, we elaborated nanoformulation o f two drugs in one
nanocapsule locating paclitaxel in the core and lapatinib on the shell periphery. With this
formulation, combining in one nanoparticle dual drugs, we reached the drugs' efficiency
synergy. In a multidrug-resistant (MDR) ovarian cancer cell line, OVCAR-3, LbL
lapatinib/paclitaxel nanocolloids mediated an enhanced cell growth inhibition in comparison
with the LbL paclitaxel-only and LbL lapatinib-only treatm ent, not to say the free one drug
treatment.
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CHAPTER 1
INTRODUCTION
In this chapter, the motivation and background for the dissertation is described. The
technology gaps for the existing drug delivery system, an introduction for sonication assisted
Layer-by-Layer technology and how it may help in solving existing problems are described.
The outline o f the dissertation is also shown. Some sections o f this chapter were published in
a paper written by the author o f this dissertation in co-authorship with Dr. Lvov and our
Italian collaborators as “ Drug-loaded polyelectrolyte m icrocapsules for sustained targeting of
cancer cells,” in Advanced D rug Delivery Reviews, v 63, 847-864, 2011. The text sections
cited from this paper is properly cited (see Ref. 27), and they are not in use in any other
dissertation.

1.1 M otivation and Background
1.1.1 Statement o f Problem and Significance
Cancer remains one o f the most challenging diseases. In America, 11.4 million people
alive have a cancer history. More than 1500 people die o f cancer every day, accounting for
one fourth o f total deaths. More than 1,500,000 new cancer cases are diagnosed yearly. The
NIH (National Institute o f Health) estimated the costs o f cancer for 2010 to be over 260
billion dollars. Among the costs, the direct medical costs were over 100 billion dollars; the
indirect loss of productivity by illness costs was over
cost was over 140 billion dollars [1-2].
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billion dollars; the indirect mortality

Traditional cancer treatments often have side effects o f killing healthy cells and causing
toxicity to patients. Therefore, it is o f great importance to develop new therapeutics which
can effectively target cancerous cells [3]. The needed features o f pharmaceutical drug
delivery (small size, biodegradability, high content o f a drug in preparation, prolonged
circulation in the blood, and the ability to target required organs) are reasonably well met by
liposomes, microcapsules, and nanoparticles for well water-soluble drugs. The development
o f nanoparticle drugs having all o f these properties for low soluble pharmaceuticals represent
a challenge.
Drug delivery systems (DDS) are designed to enhance the pharm acokinetics and
therapeutic performance o f drugs [4], In fact, they may pave the way for achieving Nobel
Prize winner Paul Erich’s “magic bullet.” One o f the intensely studied DDS is the magnetic
field manipulated drug delivery systems, because magnetic materials are biodegradable and
can be given endovascular and act at a relatively long range [5]. This system also can be
helpful for imaging [5]. However, the drug loading capacity o f these systems is relatively low
for cancer treatment, and this is even more conspicuous for the many poorly soluble drugs.
Many efficient cancer drugs (for example, paclitaxel, lapatinib, atovaquone, curcumin,
camptothecin, and tamoxifenetc) approved by FDA are poorly soluble in water. However,
their bioavailability is low for treatment, and many o f them are not only toxic to cancer cell
but also toxic to normal cells. Paclitaxel is a representative poorly soluble drug which could
be used to treat various cancers such as lung, ovarian, and breastcancers [6 ]. However, it is
very difficult to load and control its release target and rate efficiently by conventional
technique [7-10], Therefore, the application scope o f poorly soluble drugs has been confined
[11-12],
Layer-by-Layer

(LbL)

self-assembly

has

been

a

well-established

method

for

nanofabrication and nanoarchitechure build-up. L bL 's versatility can be very useful for
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building up the drug delivery system. We used Layer-by-Layer coating technology to
establish a simple, effective method for preparing multifunctional poorly soluble drug
nanoparticles which can become stable, targeted releasable, traceable, aqueous and bioactive
nanoparticles with high concentration (more than 50%) o f the active drug. Due to these
multifunctional properties, the poorly soluble drug nanoparticles could be used for achieving
our object o f early detection, diagnostics, and prognostics for cancer diseases. Here, we used
paclitaxel and lapatinib as representative poorly soluble anticancer drugs and aimed at
establishing simple, effective methods in cancer research and nanomedicine and to develop
chemotherapeutics that can target cancerous cells. O ur research was superior to micelle
carriers and other techniques in universality o f method (for micelle carrier technology,
different drug requires different condition to become soluble), m ultifunction (targeting,
imaging, proper usage o f anti-angiogenesis agents), drug concentration (more than 50%
compared with less than 5%), stability (high and low), and controllability o f release rate (easy
and difficult). O f course, in this work, we accom plished these goals only partially.
To sum up, our approach may be helpful for establishing simple in preparation stable
nanocolloids o f low soluble drugs which otherwise do not have means for delivery. For this
research, we solved the following tasks: 1) form ing o f 200-300 nm nanocores o f paclitaxel
and lapatinib through ultrasonication and modified solvation methods;
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) making stable nano

colloids o f these drugs in water, 3) making this nanocolloids stable at 0.1 M NaCl solution
and PBS buffer at concentration o f 1-2 mg/ml through architectural design o f LbL shells with
PEGylation; 4) optimizing drug release rate through adjustment o f the polyelectrolyte layer
number in the capsule shell, and 5) combining these two drugs (paclitaxel and lapatinib) in
one nanocapsules for enhanced anticancer efficiency. The nanocapsule targeting, though,
which may be performed with this method o f architectural shell through including
immunoglobulins in the outermost shell, is out o f the scope o f this work.
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1.1.2 Drug Delivery Systems (DDSt
Drug delivery systems are the development of tailored systems which help deliver a
certain amount o f one (or more) therapeutic drug(s) to a targeting point, at a certain
controlled release rate, with or without the existence o f a specific trigger [13],
The US demand for drug delivery systems (including the value o f the delivered drugs)
will increase over ten percentannually to $132 billion in 2012 [14], which will well justify
this work. In a further introductory section, we will use sections o f our review paper in
Advanced D rug Delivery Reviews, 2011, p. 847-864 with appropriate reference V. Vergaro, F.
Scarlino, C. Bellomo, M. Maffia, X. Zhang, Y. Lvov, S. Leporatti, “Drug-loaded
polyelectrolyte microcapsules for sustained targeting o f cancer cells” A dvanced D rug
Delivery Reviews, v 63, 847-864, 2011.
Oral drug delivery systems will continue to account for the largest share (50%) o f
demand through

2 0 1 2

due to favorable cost advantages, a wealth o f potential new product

applications and significant efficacy advantages over conventional dosage formulations.
Parenteral preparations will provide the strongest growth opportunities for drug delivery
systems, with demand expanding over 15% annually through 2012 (32% share). W hile the
Inhalation & Other account for 18% o f the total share. An increasing incidence o f chronic
respiratory conditions will keep demand for inhalation drug delivery systems advancing
favorably [14].
Medicines adapted to a controlled-release matrix, diffusion and reservoir systems will
post favorable sales gains as drug makers seek to gain competitive advantages by introducing
new, improved formulations o f off-patent pharmaceuticals.

Improved solubility and

pharmacokineticactions will lead to rapid growth both in the number and sales o f drug
nanoparticles [14],
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Primary goals for drug delivery systems include (i) target drug delivery, (ii) drug toxicity
reduction while maintaining therapeutic effects, (iii) greater safety and biocompatibility and
(iv) faster and lasting development o f medicines. To reach these purposes, a deep
investigation about drug incorporation and release, in order to maximize drug loaded into
nanocarriers, as well as biocompatibility and bio-distribution information are also essential
[13, 15].
The major drug delivery systems developed are micellar nanocarriers, magnetic field
manipulated

DDS,

liposomes,

dendrimers,

solid

lipid

nanoparticles

(SLN)

and

nanostructured lipid carriers (NLC), fullerenes and nanotubes (CNT & Halloysite) etc. They
are briefly discussed below.
1.1.2.1 Magnetic Field M anipulated DDS
One o f the intensely studied DDS is the magnetic field manipulated drug delivery system.
Since magnetic materials are biodegradable and can be given endovascular and act at
relatively long range [5]. Furthermore, this system can be helpful for imaging [5], Most
common magnetic nanoparticles are iron peroxide (Fe 3 0 4 ) NPs o f 15-60 nm diameters [16].
They generally are made by a magnetic core and then coated with natural or synthetic
polymers. Natural compounds widely used are carbohydrates, such as dextran, and proteins
that are usually cross-linked to avoid their degradation in aqueous solutions. Synthetic
coating materials are PEG, PLA and PVA, which have a higher mechanical strength than
other natural chemicals [17].
Other metallic nanoparticles used are gold shell nanoparticles, which have a dielectric
core covered by a thin metallic gold shell. Their properties make them useful mostly for
biomedical imaging and therapeutic applications [16]. Recently, Lee et al. developed
magnetism-engineered iron oxide (MEIO) nanoparticles for the detection o f target biological
molecules in vivo [18]. When conjugated with an antibody, M nM EIO-Herceptin conjugates
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demonstrated enhanced sensitivity for cancer cell detection as well as for in vivo imaging o f
small tumors.
However, the drug loading capacity o f these systems is relatively low for cancer
treatment and this capacity is even more conspicuous for the many poorly soluble drugs.
Besides, it is unclear how to remove inorganic components from the patient organism.
1.1.2.2 Liposomes and Micelles
Micelles are nanoscopic self-assembling core-shell structural colloidal particles, one o f
the most commonly studied drug delivery system, and in some cases, micelles can serve as
drug delivery systems for poorly soluble pharmaceuticals. Their hydrophobic cores can be
used for encapsulation o f many poorly soluble drugs with increased stability and good
biocompatibility [7-10].
However, micelles are far from satisfactory because o f their low loading efficacy,
problems with controlling the release rate o f the drug and other problems.
Liposomes are small vesicles composed by amphiphilic phospholipids enclosing an
interior aqueous space, within the range

o f 50 to

1000 nm

[19],

Phospholipids

(phosphatidylcholines, usually called “lecithin”) are the main constituents o f liposomes, and
due to their amphipathic properties, they readily form concentric bilayers. The most comm on
laboratory protocol used to create liposomes consists o f sonication, extrusion, reverse-phase
evaporation, and solvent injection approaches [20], Depending on their size and the num ber
o f bilayers, liposomes can be classified into three categories: multi-lamellar vesicles (MLV),
large uni-lamellar vesicles (LUV) and small unilam ellar vesicles (SUV). The major problems
associated with liposomes are their stability, poor batch-to-batch reproducibility, difficulty in
sterilization, and low drug loading capacity.
Liposomes and micelles are the most common nano/micro vehicle for delivery o f low
soluble anticancer drugs; however, their low stability and low 2-3% loading capacity confines
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their application efficiency. In our research, we collaborated with the Pharmacy Department
o f Northeastern University, the group o f experts who pioneered micellar formulation for
anticancer drugs (V. Torchilin), and their experience allowed us to understand and exploit
LbL technique abilities to add new features for nanocapsule formulation (e.g., higher stability,
and higher drug loading).
1.1.2.3 Dendrimers
Dendrimers are repeatedly branched polymeric macromolecules [19]. Dendrimers have
three components: an initiator core, branches, and terminal functional groups. The core is
frequently named (GO) to which are linked first generation monomers (G l), while second
generation monomers (G2) are linked to corresponding G l monomer in a 2:1 ratio and can be
properly functionalized coherently with drug delivery application [19], Further steps o f
generations create the dendrimer and its m olecular weight doubles with each additional
generation. The main advantages o f the dendrimers are (i) nanoscale sizes, (ii) high numbers
o f terminal surface groups (Z) suitable for bioconjugation, (iii) an internal hollow space
which can encapsulate small molecule drugs and (iv) Non- or low immunogenicity due to
PEGylation.
1.1.2.4 Solid lipid nanoparticles (SLN) and Nanostructured
Lipid Carriers (NLC)
SLN and NLC have been developed very recently and can be easily synthetized. SLN are
lipid-based drug-delivery carriers with nanometer to sub-m icrom eter scale size (50-1000 nm)
after drug encapsulation; moreover, they have a lipid, biocompatible and biodegradable
composition and do not require the use o f organic solvents for their assembly. The SLN
particle synthesis protocol, which involves high-pressure homogenization techniques, can be
performed at a lower cost and can be easily scaled up [20]. NLC, similar to SLN, are
colloidal particles that typically range in size from 100 to 500 nm. They are composed by
solid- and liquid-phase lipids, but are generally solid attemperatures above 40 °C. In contrast
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to the lipid crystal matrix o f SLN, the lipid matrix o f NLC has an imperfect crystal or
amorphous structure. This structure allows for drug loading in both them olecular form and in
clustered aggregates. Both SLN and NLC have been successfully m ulti-functionalized to
target specific cells, and to release drugs in a controlled manner [20]. SLN and NLC
advantages consist in i) controlled drug delivery and release ii) particularly feasible for
synergistic multiple drugs encapsulation, and iii) increased blood circulation half time and
exploiting EPR retention on tumor sites. Hydrophobic drugs with short circulation half-lives
are ideal candidates for delivery via SLN and NLC [20],
1.1.2.5 Fullerenes and Nanotubes (Carbon nanotubes & Hallovsite')
Fullerenes have a polygonal structure made up by 60 carbon atoms and can be easily
functionalized. Their diameter is 0.7 nm, but they have a poor solubility in aqueous solvents
and are likely to create supramolecular aggregates, thus they are hardly used in biomedical
applications. This problem has been solved functionalizing fullerenes. Amphifullerene
compounds are functionalized fullerenes, based on a C 6 o core, which contain both
hydrophobic

(water-insoluble) and hydrophilic (water-soluble) moieties, called AF-1

monomers, and self-assemble to form supram olecular structures referred to as “buckysom es”
[21]. Buckysomes are self-assembled, water soluble fullerenes used for drug delivery
approaches, such as the paclitaxel-embedded buckysomes (PEBs). Currently, in vitro and in
vivo preclinical studies are available, since these structures have not been tested in clinic.
Carbon nanotubes (CNTs) consist o f a single sheet of graphite rolled to form a cylinder
[16]. CNTs can be used as carriers for the delivery o f drugs, DNA, proteins and other
molecular probesinto cells [22], Early experimental studies regarding interactions between
MWNTs and proteins revealed that both biomacromolecules and synthetic molecules can be
adsorbed over the CNTs' surface [23, 24] and/or fill the internal cavity o f these cargo-carriers
[25].
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For drug delivery, these approaches seem more useful for introducing drugs into interior
cavity o f tube, whose open ends might be capped to generate a nanopill [25],
However, the main problem o f Fullerenes and CNTs as drug nanocontainers is their
toxicity and low drug encapsulated concentration. We do not foresee practical results based
on these drug delivery nanosystems.
Halloysite clays are two-layered rolled aluminosilicate, chemically sim ilar to kaolin,
with hollow tubular structure in the submicrom eter range. The size o f halloysite particles
varies from 50 to 70 nm in external diameter, 15 nm diam eter lumen and 1-0.5 pm length
[26]. Their preparation can be made with inexpensive materials and simple protocols of
fabrication. Moreover, halloysite nanotubes have different chemistry in the inner and outer
surfaces, and this property can be exploited for different and peculiar m odification o f inner
and outer walls [26], Halloysite nanotubes are much more bio-friendly than carbon nanotubes
(they are just clay used by people for thousand years); however, again, they are inorganic and
cannot be used for intravein blood injection because they are not biodegradable.
1.1.3 Drug Delivery M echanisms
There are mainly two types o f drug delivery mechanisms: 1) passive targeting through
the enhanced permeability and retention (EPR) effect and 2) active targeting through
attachment o f special targeting agents. Passive targeting is ubiquitous but it has some
disadvantages such as low drug delivery efficiency and difficulty in controlling the process.
The advantage o f Layer-by-Layer self-assembly technology is the wide choice o f materials
for building up the architectures. Those active targeting agents can be used and incooperated
into the nanoarchitectures for active targeting to the cancer cells and, therefore, improve the
efficiency o f cancer treatment and reduce o f toxicity [28],
As can be seen from Figure 1.1 [27], in passive targeting, the vasculature supplying
cancer lesions might have increased endothelial fenestrations and architectural anarchy,
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resulting in the preferential extravasations and protracted lodging of injected particulates. The
active targeting is conjugation o f active recognition moieties to the surface of a nanovector.
The active targeting requires specific drug delivery system. In our case, the versatility o f
Layer-by-Layer technology

in choosing different compositions for building up the

nanoarchitechure and the ability to control the size will provide a very powerful drug carrier
system.

Passive drug targeting

^
ET 1 O |

Tumour

Cancer cell targeting

T
v<
Tumour | *
8
b] Normal
tissue |

'f lf /
*J *

8
I

r^ri
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Figure 1.1 Passive targeting (left) and active targeting (right) [27]

1.2 M eth o d o lo g y for M u ltifu n ctio n a l P oorly S oluble D ru gs
The application scope o f poorly soluble drugs has been confined due to the difficulty to
load and control its release target and rate efficiently by conventional techniques. Here, the
technology gaps and how our technology can solve these problems will be discussed.

1.2.1 Technology Gaps
Poorly soluble drugs are very difficult to load and control its release target and rate
efficiently. The main gaps for enlarging the application of poorly soluble drugs are listed as
follows: The first gap is to produce aqueous nanoparticles o f poorly soluble drugs with high
concentration (more than 50%) o f the active drug [28], The second gap is about endowing
poorly soluble drugs with high targeting selectivity [28] and imaging capability. The third

gap is to simultaneous targeted released and imaged more than one drug or one drug and one
anti-angiogenic agents at one time. (These drugs can be soluble or poorly soluble).
These three gaps have important theoretic and practical significance for enlarging use of
drugs and recovery from disease. Because o f the intrinsic poorly soluble property o f many
drugs, it is thus very difficult to load them and control their release target and rate efficiently.
Targeting selectivity is mainly concerned with the technology to endow drugs' high
differential uptake efficiency in the target cells over normal cells via specific ligands [3],
while the biological solubility, stability and the ability to overcome the barriers are concerned
with the technology for dissolving insoluble drugs effectively. These two directions are
interrelated and have some influence on each other towards the purpose o f this research. The
target selectivity study is important for both soluble and poorly soluble drugs. The
technology for dissolving insoluble drugs effectively so that they can be as effective as
soluble drugs is even more important for the com m ercialization of these drugs, and through
careful design o f the Layer-by-Layer coating technology, these three goals may be well
solved. To sum up, they are interrelated and synergistic goals to increase the efficacy o f
poorly soluble drugs, and they all are very important part o f this research.

1.2.2 Laver-bv-Laver Technique
Layer-by-Layer assembly is a unique technique for the fabrication o f composite films
with nanometer precision. The attractive feature o f this approach is its ability to assemble
complex structures from modular components, and integrate them into self-assembling
constructions for a wide range o f applications [29-35],

1.2.2.1 Laver-bv-Laver Approach
As can be seen from Figure 1.2, Layer-by-Layer self-assembly o f m ultilayer films
involves the construction o f complex composite materials with precise film thickness, one
layer at a time, enabling the development o f novel structures and devices with properties
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tailored by controlling the molecular makeup and arrangement. Early fundamental studies of
multilayer assemblies on planar substrates demonstrated the practicality and versatility o f the
approach, and work over the past decade has included further investigation into the internal
structure and composition o f LbL films, including dynamic and long term interactions
between film components, solvents, and solute, especially transport properties. Beyond
assembly onto flat planar surfaces, the multilayer deposition via LbL has been extended to
colloidal templates, leading to elaborate modification o f particles and even to hollow
capsules, both o f which are exciting and attractive for many applications. While the bulk o f
work in LbL has been in experimental investigations, some efforts to generate theoretical
descriptions for the multilayer assembly have also been undertaken, although much more
work is needed in this area to establish useful models for design of devices based on this
approach. Finally, applications for LbL films abound and are now being pursued at the
academic level, with some examples o f industrial applications for eye lens modification,
improvement o f cellulose fiber for better fabric and paper, microcapsules for insulin
sustained release, and others [31-35].

Polvcation/polyauion
bilayer, D= 1 2 nin

N anoparticle/polvion (or protein)
bilaver, D = 5-50 nm
Figure 1.2 Layer-by-Layer (LbL) self-assembly ideology [34]

As was demonstrated by Decher et al. [31] in Figure 1.3, Layer-by-Layer self- assembly
approach consists o f alternate absorption o f polyanions, such as PSS (poly (styrene
sulphonate)) and DXS (dextran sulphate), and polycations, like PAH (poly (allylamine
hydrochloride)) and PRM (protamine dextran). The technique takes advantage o f attractive
electrostatic forces between charged polymers and oppositely charged surfaces, and film
growth is achieved stepwise by the repetitive exposure o f substrates to dilute polycation and
polyanion solutions.
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Figure 1.3 Layer-by-Layer (LbL) self-assembly set-up and process [31 ]

Hydrophilic and positively charged substrates are immersed into the solution o f
polyanion (negatively charged polymer, for example, PSS) for several minutes. As a result, a
thin layer (thickness

1-2 nm) o f the polymer is adsorbed on the surface. Charge

overcompensation leads to a negative surface re-charging. Then, the substrate is washed (a
washing step is needed to removenot adsorbed material) and placed into the solution with
polycation (positively charged polymer, for example, PEI). The polymer is attached
electrostatically to the charged surface. The process can be repeated several times to reach a
defined multilayer thickness controlled by layer coating cycling. As depicted in Figure 1.3,
the iterative dipping o f a substrate (e.g. a glass microscope slide) into solutions o f oppositely
charged polyelectrolytes yields multilayered films composed o f alternating layers o f cationic
and anionic polymers. The thicknesses o f these films typically range from tens or hundreds o f
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nanometers to up to several micrometers, depending on the number o f layers deposited and
the solution conditions (e.g., pH, ionic strength, etc.) used during fabrication.
This polyelectrolyte multilayer coating can be easily and reproducibly formed on the
surface o f any charged substrate. By varying the charge density on each polymer or the
number o f coating cycles, substrates with a different surface charge and different composition
o f the polymeric coat can be prepared. Layer-by-Layer technique o f assembly permits the
deposition o f thin films on a wide variety o f macroscopic, microscopic, and nanoscopic
objects [36-41].

1-2.2.2 LbL Drug-Loaded Polyelectrolyte Microcapsules
Several groups have used tem plating Layer-by-Layer assembly to fabricate hollow
multilayered capsules by depositing polyelectrolytes onto cores that can be dissolved,
degraded, or otherwise removed after film formation. Experiments are reviewed by
references [39, 41-49], This approach has been used widely to develop approaches to either
encapsulate or deliver a wide range o f m acromolecular agents. In fact, packaging o f drugs
into micro- or nanocarriers

has sparked great interest on biological validation

of

micro-to-nanoscale delivery systems for targeted therapy [50-51]. For therapeutic purposes,
there is a clear need to fabricate supramolecular assemblies o f drug and functional carrier
materials which would be biocompatible and biodegradable under physiological conditions
[52-53]. In this respect, hollow microcapsules are of particular interest, as they can be
fabricated via Layer-by-Layer (LbL) assembly o f oppositely charged polyelectrolyte
multilayers o f dextran sulfate (DXS), protamine (PRM) or poly-L-arginine (PLA) that are
degraded by intracellular proteases or hydrolytic enzymes, around a sacrificial core o f
calcium carbonate (of few hundred nm to several micrometers o f diameter) that is dissolved
by EDTA after deposition [54-55], Due to the versatility o f electrostatic interactions,
properties and functionalities o f the resulting hollow capsules (i.e. their encapsulation or
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release efficiency), can be finely tuned in the nanometer range by varying capsule wall
thickness and number and composition o f the polymeric layers, hence their permeability in
response to changes on the pH, ionic strength or solvent [42],
The intrinsic advantage o f LbL fabrication method is unmet by any other technique, as it
lies in the potential o f entrapping simultaneously drugs, fluorescent probes or colloid
nanoparticles (e.g. quantum dots or magnetic particles) with tunable functionalities into the
biodegradable multilayers o f one unique hollow capsule (post-loading m ethod) [42, 56-57].
Polyelectrolyte microcapsules can be fabricated by LbL technique previously described.
After the consecutive assembly o f oppositely charged polymer layers around the CaCOj core,
the core itself is removed to obtain hollow and stable capsules whose inner cavity and
polymer wall can be loaded and functionalized, respectively, with a variety o f substances
such as m olecular dyes, drugs, biomolecules, which retain their distinctive properties after
the embedding procedure [49, 58]. The resulting hollow capsule usually has a wall thickness
o f between a few tens and several hundred nanometers and have a diameter ranging from tens
o f nanometers to several micrometers, depending on the size o f the original core [49, 58],
The forming of the hollow capsule is illustrated in Figure 1.4.

■mu u
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Figure 1.4 Formation and release o f LbL assembly capsules [58]
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Particularly, the initial step o f nanoparticle formation is the creation o f CaCCL core
mixing soluble salts o f Ca 2 , as CaCL, and CO 3 2' compounds, like Na 2 CC>3 . The mixture
results in an amorphous precipitate initially, which subsequently transforms into aggregated
CaCC>3 microcrystals with a particular morphology. The CaCCL microparticles obtained by
this simple route are uniform and hom ogenously sized, non- aggregated, high porous spheres.
The quality o f the resultant microparticles was found to be strongly dependent on the
experimental conditions such as type o f salts used, their concentration, pH values,
temperature, and rate o f solution mixing and intensity agitation of the reaction mixture [59,
60], After core building, the LbL covering occurs, using an alternate layering o f polyanions
and polycations (DXS-PRM and PSS-PAH). Once a multilayered layer has been created,
CaC 0

3

core dissolution occurs by saline solutions (e.g. sodium hypochloritesolution) or

ethylenediaminetetraacetic acid (EDTA). The core dissolution makes an empty cavity,
subsequently loaded with a drug, like paclitaxel. Two fundamental components for capsule
fabrication are the core templates and the polyelectrolyte pairs. An ideal tem plate has to be
stable under the LbL process, soluble in mild conditions and completely rem ovable from the
inside o f the capsules without affecting the morphology and stability o f the multilayer
assembled on top o f it. In recent years, num erous materials have been employed as sacrificial
templates such as polystyrene latex, melamine formaldehyde (MF), SiCL, carbonate particles
(MnCCL, CaCCL, CdCCL) and biological cells like erythrocytes [49, 58], The assembly of
Latex is shown in Figure 1.5 as an example.
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Figure 1.5 LbL assembly o f Latex [34]

The capsule wall is also crucial for the fabrication o f functional capsules, as their
permeability or porosity strongly depends on the chemical structure and the m olecular weight
o f the employed polyelectrolyte pairs. The majority o f polyelectrolyte capsules described in
literature

are

composed

of

pairs

of

synthetic

biocom patible-not-biodegradable

polyelectrolytes such as anionic poly (sodium) styrene sulphonate and cationic poly
(allylamine)

hydrochloride,

or

composed

of

biocompatible

and

biodegradable

polyelectrolytes such as dextran sulphonate and protamine sulphate, which are more suited
for therapeutic use. The mechanical/elastic properties o f polyelectrolyte capsules are
influenced byseveral parameters such as the chemical nature o f the polymer used, which can
cause weak or strong intermolecular interactions with the multilayer, and the m olecular
composition o f the innerpart o f the capsules [54],
LbL deposition onto charged polystyrene (PS) particles in solution was firstly exploited
by Caruso and co-workers [54] to construct hollow polyelectrolyte shells through the
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stepwise adsorption o f polyelectrolytes onto a decomposable colloidal template. This
template was subsequently removed after formation o f the multilayer shells was realized.
Instead o f PS particles weakly cross-linked melamine formaldehyde (MF) colloidal particles
were used by Donath et al. [55], These particles decompose in aqueous media at pH values
below 1.6. The PSS/PAH polyelectrolyte multilayer film was built up beginning with
adsorption o f the negatively charged polyelectrolyte onto the positively charged MF particles.
When these coated MF particles were exposed to low pH, the core decomposed [55], and the
residual MF oligomers were expelled from the core, since they could permeate through the
polyelectrolyte layers that form the shell. These MF oligomers were separated from the
hollow shells by centrifugation. MF particles are widely used as core templates and have
been very well characterized. They are favored above PS particles because o f their
decomposable character but have several disadvantages, such as their low biocompatibility.
Furthermore, the oligomers formed after decomposition can partially remain inside the
polymer wall during the dissolution process, and there is an increased resistance or difficulty
to decomposition upon time. In order to overcome these disadvantages, other biocompatible
and decomposable templates for LbL techniques have been investigated [61]. The two mostly
studied template materials are poly-DL-lactic acid (PDLA) and poly (DL-lactic-coglycolic
acid) (PLGA). Degradable microparticles based on these biopolymers were prepared using
the oil/water emulsion-solvent evaporation technique. PSS and PAH were chosen as
polyelectrolytes to coat onto the biodegradable templates. The next step was the removal of
the core by dissolution, which was achieved by dissolving the polymers in a mixture o f
NMP/acetone in a 1:1 volume ration [61], Instead o f an MF core, metal carbonate crystals
were also used by Ma et al. [62], These cores can be removed easily by EDTA solution. The
advantage o f using these organometallic polymers for incorporation into the capsule walls is
that they allow changing the permeability o f these walls. The CaCCL template particle has
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found use for encapsulation o f biological compounds, since it can be dissolved under healthy
conditions.

1.2.2.3 LbL Drue-Loaded Polyelectrolyte Nanocolloids
A natural extension o f previously described approach is the deposition o f polyelectrolyte
films on nanoparticles (drug or inorganic) leading to coated nanocolloids. In this respect our
group developed recently drug-nanocolloids [63], These novel entities are stable aqueous
polyelectrolyte multilayer shells built on drug particles with few nanometer wall thicknesses
(up to 100 nm) and made through a LbL assembly, which consisted in an alternate adsorption
o f oppositely charged polyelectrolytes onto solid templates [63]. LbL coating technology was
used to make stable aqueous nanocarriers o f poorly soluble drugs with a high content o f the
active drugand controllable drug release rate. To achieve this goal, aqueous suspensions of
poorly soluble drugs with micron range particles are subjected to the ultrasonic treatment in
order to decrease the size o f individual drug particles to the nano level (between 100 and 200
nm), while keeping the nanoparticles formed under the sonication to prevent their fast
agglomeration, stabilize them in solution by applying the LbL coating (alternating addition o f
polycations and polyanions to the system) and assembling thin polyelectrolyte shells on their
surface. In the assembly process, the highly charged polymeric layer was formed on the drug
particle surface after the first polymer application, and this layer prevents drug particle
aggregation after terminating the sonication. At the end o f the process, stable coated
nanocolloidal drug dispersions were formed with high drug content in each particle (between
50% and 90%) [63]. Moreover, it wa also possible to functionalize nanocolloids using a
polymer containing reactive groups (such as amino orcarboxylic groups) for the last “outer”
surface layer, thus allowing the linking o f specific ligands, or reporter groups, and other
moieties o f interest to drug nanoparticles such as monoclonal antibodies [63].
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1.2.3 Sonochemistry
One o f the central problems for LbL nanoformulation is formation o f the initial drug core
o f 200-300 nm in diameter. We solved this problem with bulk drug ultrasonication with
simultaneous polycation deposition stabilizing formed dispersion. Sonochemistry will enable
“green” chemistry without environmentally harmful chemical by-products. Com pared to
different sources o f the energy input into the reaction, ultrasonic treatment can induce a wide
range o f chemical reactions

in non-equilibrium

state

applicable for synthesis and

modification o f products with new physico-chem ical characteristics and catalytic activity.
The effects o f ultrasound derive primarily from cavitation, where bubbles collapse in liquids,
which results in an enormous concentration o f spatially confined energy. This energy is
derived from the surface and kinetic energy within the liquid converted into heat and
chemical energy imparted to resulting materials [64-66]. Nanoparticle synthesis is often
based on control o f nucleation and crystallization [67-69], The vision o f the proposed project
was to achieve a breakthrough in ultrasonic synthesis by employing surface-active materials
(amphiphilic

polymers,

polyelectrolytes, surface-functionalized

nanoparticles, etc.)

as

regulators to control the interfacial parameters o f the cavitation process on nano level during
formation and collapse o f microbubbles. Introducing the surface-active materials at the
cavitation interface will enable one to control the temperature and pressure inside bubbles, to
control the energy balance and ways o f energy dissipation. The proposed approach will help
in controlling the structure and physical state o f the cavitation interface and develop new
methods for one-step sonochemical synthesis o f nanoparticles with core-shell structures.
Figure 1.6 is the set-up for sonication study. Ultrasonication can be applied to create
extreme physical-chemical conditions at the liquid/gas interface; whereas, the bulk solution
can stay at room-temperature.
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Figure 1.6 Set-up for sonication study [66]

During high-power ultrasonication (20 kHz, 50-100W ), gas bubbles were formed and
expanded, followed by cavity implosion and je t formation (Figure 1.7).

Figure 1.7 Cavity implosion and jet formation [66]

The cavity implosion created very high temperature (up to 5000 K) (Figure 1.8) and high
pressure (up to 103 atmosphere) in the center o f the cavity, while the bulk solution remained
at low-temperature because o f localized energy release and high cooling rate. This high
pressure and the jet formation crushed solid materials into micro- and nanoparticles [64-68],
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Figure 1.8 Cavity temperatures [66]

Figure 1.9 schematically illustrates the control mechanism over cavitation process. Initial
mixture

contains

initial

reagents

and

surface-active

materials

with

regulated

hydrophobic/hydrophilic balance. During ultrasonic treatm ent and formation o f microbubbles,
these materials go to a liquid/gas interface changing the surface energy o f the microbubble
and, as a result, final energy and its partition ratio (between thermal and chemical) during
microbubble collapse [64-70],

u ltrasound

^

C ontrol over:
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so n o lu m in e sc e n c e ,
so n o sy n th e sis,
en erg y co n v ersio n ,
c atalysis

Figure 1.9 Schematic illustration o f cavitation process

In our study, sonication was performed in the presence o f surface-active agents to ensure
their adsorption at the cavitation interface. These surface-active agents had the effect o f
stabilization and to increase o f the lifetime o f the cavitation microbubble up to second range
(Figure 1.10).
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Figure 1.10 Lifetime o f the cavitation microbubble [66]

The precursor reagents (bulk m aterials, monomers, and colloids) were added after
starting the sonication in the presence o f already adsorbed surface-active material (Figure
1 . 1 1 ).
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Figure 1.11 Adsorptions o f surface-active materials onto the nanocolloids

To sum up, there were mainly three effects power sonication had: cavity with high
temperature, jet flow generated after cavity collapse, and polyelectrolyte enrich on the cavity
surface.
In order to attempt to decrease the diam eter o f the formed nanocores o f paclitaxel, we
developed two experimental techniques to increase energy o f bubble collapsing (bubble
formation enhancers) and elevated gas pressure which will be described further.
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1 .2.4 Methodology r70-751

We used paclitaxel and lapatinib as representative poorly soluble anticancer drugs and
aimed at establishing a simple, effective method which can be helpful for yielding advances
in early detection, diagnostics, prognostics and the selection o f various therapeutic strategies.
Our project focused on the study on ultrasonication assisted Layer-by-Layer technique
for preparing multifunctional paclitaxel and lapatinib nanoparticles. Figure 1.12 shows the
methodology.

First,

powerful

ultra-sonication

was

applied for m aking

small

drug

nanoparticles o f desired size and suitable shape. Second, the Layer-by-Layer self-assembly of
multilayer films was applied for building up the novel structures with properties tailored by
controlling the molecular makeup and arrangem ent with nanoscale precise film thickness. In
this process, a nanoarchitectural approach designing layers o f different components,
including ones serving as diffusion barrier and outermost layers containing targeting agents,
can be realized. Third, the well prepared drug nanocolloids were delivered to the cancer cells
for treatment o f cancer.

Nanocolloids (i.e.
an tica n ce r drug)

idivery of Nanoccrriers into Cancer Cells

Cellular d ea th (A p o p to sis)

Figure 1.12 Methodology

1.2.4.1 Preparation o f Hydrophobic Drug Particles with
Desired Size and Suitable Shape
Our first step was to prepare hydrophobic drug particles with desired size and suitable
shape. Powerful ultra-sound generates micro-bubbles in liquid. These micro-bubbles will
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collapse in microseconds. If any solid particle is near the bubble, jet fluid and shock waves
will hit the particle and break it during collapsing [64-75]. The particle will have a wide
range o f size since the ultrasonic process for breaking down the particles is a mechanical
process. Sonication power and time both have effect on the particle size distribution. In
general, higher power and longer time will result in smaller particles. While adding
polyelectrolyte into the solution, the negative surface o f the newly formed surface will help
keep particles away from forming aggregation. Thus smaller particle size can be achieved
with better size distribution. Polycations were added during the sonication process to adsorb
drug nanoparticles and were thus prevented from re-aggregation. Surface potential of
particles will become more positive during this process for the influence o f polycations.

1.2.4.2 Design and Implementation o f the Layer-by-Layer
Coating Technology
Different num ber o f layers and different polyelectrolyte types will affect the drug release
rate. To obtain sustained release, the coating structure needs to be carefully designed (to
obtain optimum release property). An anti-angiogenesis agent such as combretastatin-A4 will
also be coated as a layer outside the core drug layer which is expected to be released before
the drug to stop the cancer cell from growing larger. After that, we will use the LbL
technology to efficiently bind drug nanoparticles to special targeting ligands to kill cancer
cells. We will carefully design the coating structure to obtain the optimum release property.
The outside layer will be coated with magnetic particles to target delivery and trace the drug
particles to specific cancer cells.

1.2.4.3 PEGylation and Controlled Release Study
To further improve our DDS for cancer treatment, stealthy (PEGylation) technology was
carried out for increased solubility, stability and drug circulation time. The formula for PEG
is HO-(CHCHO) n -CHCH-OH. A controlled release study has also been carried out.
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Our research is superior to micelle carrier and other drug delivery techniques in
universality o f method (for micelle carrier technology, different drugs require different
condition to become soluble), drug concentration (more than 50% compared with less than
5%), release rate (easy and difficult controllability), and stability (high and low), and
simultaneously release o f more than one drugs.

1.3 O u tlin e
Chapter One introduces the motivation and some background information o f this
research work. It also gives a brief literature review covering the knowledge needed for this
dissertation:

cancer treatment and

drug delivery

systems,

LbL

nanoassembly,

and

sonochemistry. Our methodology for multifunctional poorly soluble drugs is shown. The
research goals and the organization o f this dissertation are discussed as well. Chapter Two
describes materials and instruments used for the research. Chapter Three discusses the
top-down approach and bubbling agent approach for preparing paclitaxel nanocores. Their
optimization processes are also presented. Chapter Four describes the bottom-up approach for
preparing paclitaxel and lapatinib nanocores (first concentrated solutions o f these drugs were
dissolved in DMSO or alcohol to make molecular solution, and then controlled nucleation o f
drugs were induced by water addition to decrease the solubility). The surfactant additives
arrest growths o f the formed cores, allowing the formation o f drug particles with the
diameters in the range o f 150-200 nm. Chapter Five demonstrates colloid stabilization with
the PEGylation and controlled release study o f those drug nanocolloids using adjustment of
polyelectrolyte layers in the shells. Chapter Six describes the dual drugs encapsulation
paclitaxel and lapatinib. Chapter Seven concludes the results o f the dissertation. Some issues
and topics for future work are recommended and a list of publications and presentations on
this work are given.

CHAPTER 2

MATERIALS AND INSTRUMENTS

2.1 M ateria ls
The two low soluble drugs, paclitaxel and lapatinib were purchased from

LC

Laboratories, Inc. (Woburn, MA).
There are two types o f polyelectrolytes used for Layer-by-Layer self-assembly:
polycations

and

polyanions.

Poly

(dimethyldiallyl

ammonium

chloride)

(PDDA),

Polyallylamine hydrochloride (PAH) are used as highzeta-potential polycations. Polylysine
(PLL), PEGylated poly lysine (PEG-b-PLL), Protamine sulfate ( PS )and Chitosan are used as

biocompatible polycations. Poly (acrylic acid) (PAA), Sodium polystyrene sulfonate (PSS)
are used as highzeta-potential polyanions. Alginic acid (AA), Heparin, Bovine serum
albumin (BSA), and Chondroitin sulfate (CS) are used as biocompatible polyanions. They are
used at the concentration range from 1-3 mg/mL. All polycations and polyanions were
bought from Sigma-Aldrich. PBS buffer, DMSO, N H 4H C O 3, Ethanol, Acetone, FITC ,

TWEEN 80 and PVP were also purchased from Sigma-Aldrich.
Reagents and Cell culture for dual drug study: The PI3K. inhibitor, LY294002, and the
ERK 1/2 inhibitor, U 0126, were purchased from Santa C ruz Biotechnology (Santa Cruz,
CA). Rhodamine (TR1TC) conjugated phalloidin, were purchased from Sigma-Aldrich. The
antibodies against cofilin, p-cofilin (ser-3), Akt, pAkt (ser 473), cyclin D1 and Tubulin were
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purchased from Santa Cruz Biotechnology. Inhibitors for PI3K and ERK, paclitaxel were all
dissolved in DMSO.
The ovarian cancer cell line OVCAR-3 and the breast cancer cell line MCF-7 were
maintained in Dulbecco’s modified Eagle’s medium (DM EM ), supplemented with 10% fetal
bovin serum, 2 mM glutamine, lOOU/ml penicellin and 100 pg/ml streptomycin, and cultured
at 37° C in a humidified atmosphere o f 5% CCE. Cells were subcultured every three days.

2.2 In stru m en ts

2.2.1 Ultrasonicator
A UlPlOOOhd Ultrasonicator (Heilscher, Germany) (Figure 2.1 (a)) was used as powerful
ultrasonicator. It came with a titanium sonotron and its working power was 15 W /cnr.
A Branson 1510 Ultrasonicator (Figure 2.1 (b)) was used as a standard ultrasonicator. An
ice/water mixture was used as a cooling agent during ultrasonication. During ultrasonication,
the ambient temperature is cooled down by the ice/water mixture.

Figure 2.1 (a) powerful ultrasonicator (power: 15 W /cm2) (b) standard ultrasonicator

2.2.2 C entrifuge
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An Eppendorf Centrifuge 5804R (Figure 2.2) was applied for centrifugation o f drug
nanoparticles.

Figure 2.2 Centrifuge

The centrifugation speed range is from 0-15,000 rpm (rotate per minute). Generally,
2000 rpm was applied for precipitation o f bigger particles (size larger than 500 nm) for 10
minutes. Centrifugation at 12,000 rpm for 10 minutes was applied for the separation o f the
drug nanoparticles from the solution (solvent, additional polyelectrolytes, surfactants and so
on).

2.2.3 ZetaPlus Microelectrophoresis Equipment
ZetaPlus M icroelectrophoresis equipment (Brookhaven) (Figure 2.3) has been applied
for the measurements o f particle size and £ (zeta) -potential. Successful sequential coating

o f oppositely charged polyelectrolytes can be measured by the electrical surface ^-potential

changes.

Figure 2.3 ZetaPlus microelectrophoresis equipm ent

Figure 2.4 shows the mechanism for Zeta potential. Zeta potential refers to the
electrostatic potential generated by the accumulation o f ions at the surface o f a particle. For
determining zeta potential, a controlled electric field is applied via electrodes immersed in the
sample suspension, and this causes the charged particles to move towards the electrode of
opposite polarity. Viscous forces acting upon the m oving particle tend to oppose this motion
and equilibrium is rapidly established between the effects o f the electrostatic attraction and
the viscous drag. The particles, therefore, reach a constant "terminal" velocity. This velocity
is dependent upon the electric field strength or voltage gradient, the dielectric constant and
viscosity o f the liquid, all o f which are known, and the zeta potential. It is usually expressed
as the particle mobility which is the velocity under unit field strength. In practice, zeta
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potentials are usually negative (i.e. the surface is negatively charged), but they can lie
anywhere in the range from -100 to +100 mV.

in sid e erf th e ceti (m e a s u re m e n t c o m a n w t

Ionte stationary bad layer
<ion fixed layer bad!

Original P?atifle

Figure 2.4 Mechanism for Zeta potential (From ref. 74)

2.2.4 Light Scattering Detectors
Precision detectors PDExpert Light Scattering W orkstation (Figure 2.5) was also applied
to double check the particle size.

Figure 2.5 Precision light scattering detectors

The workstation provides molecular size and conformation data from the autocorrelation
o f dynamic light scattering signals at any user-selectable angle in five degree increments on a
360° platform. It is also known as quasi-elastic light scattering (QELS) or photon correlation

spectroscopy (PCS). It can be applied for the recording o f the scattered light intensity
changes on ps time range for individual particles' Brownian motion. It is quantified as an
exponential function under the assumptions o f low concentration, spherical size particle and
known viscosity o f its environment.
It provides accurate measurements for hydrodynamic radius (Rh) and hydrodynam ic
radius distributions from any type o f sample ranging from molecules (protein and antibody)
to nanoparticles such as liposomes, sols, magnetic particles, emulsions etc.

2.2.5 Confocal Microscope
A Leica TCS SP2 laser scanning confocal m icroscope (Leica M icrosystems, Inc.)
(Figure 2.6 ) was applied for visualization o f the fluorescent FITC labeled onto the outmost

polycation layer o f the drug nanoarchitechure for the shell composition confirmation.

Figure 2.6 Confocal Microscope

Confocal microscopy has been widely used in the investigations o f biological and
medical thin optical specimens imaging for thickness up to 100 pm. The confocal
microscopy is equipped with several high-speed acousto-optic tunable filters (AOTFs) laser
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systems. Therefore, it can have excellent wavelength and excitation intensity regulation. Its
minimum detectable size is around 400 nm.

2.2.6 Scanning Electron Microscope
A Hitachi S 4800 FESEM (field emission scanning electron microscope) (Figure 2.7)
was used for particle morphology imaging and size measurement. Prior to imaging,
De-Ionized water was used to wash samples for three times. Samples were then diluted 10
times and put onto silicon wafer. When the samples were dried, they were applied for
imaging. An EDX detector included in the FESEM can be applied for the element
composition analysis.

Figure 2.7 FESEM

2.2.7 X -ray D iffracto m eter (X R D )
A Bruker D8 Discover XRD (X-ray diffractometer) (Figure 2.8) machine was applied for
non-destructive crystal structure and chemical composition determination o f drug samples.
The XRD is a tool for the observation samples by detecting the scattered intensity after being

hitted by X-ray beam. The XRD measurement is based on the Bragg's law: 2d sin0=n/L For
the function, 0, X and d are the scattered angle o f the X-ray, wavelength o f the X-ray
and d-spacing o f the sample resepectively. The d-spacing is the distance between crystalline
planes, which gives information about the sample.

Figure 2.8 XRD

2.2.8 UV Spectrophotometer
An Agilent 8453 UV spectrophotometer (Figure 2.9) was used for detection o f the drug
concentration. Its applicable wave length is from 190 to 1100 nm. For those low soluble
drugs, paclitaxel absorbance was measured at 245 nm in Ethanol and PBS. Lapatinib
absorbance was measured at 365 nm in DMSO and PBS/TW EEN 80.
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Figure 2.9 UV spectrophotometer

2.2.9 Release Chamber
The release study o f those drug nanoparticles was carried out using two 1 ml standard
horizontal diffusion chambers (Figure 2.10). There are m ainly five components o f the
diffusion chambers as listed in Figure 2.9. In between these tw o diffusion chambers, 0.2 pm
pore size acetate membranes are used for the diffusion o f drug molecular. In each diffusion
chamber, a magnetic stirrer was put inside for the uniform dispersion o f drug nanoparticles.
The whole release set-up was placed on a magnetic stirring system, and then 1 ml o f drug
dispersion was added into one side o f the chamber, while 1 ml of PBS was added into the
other side o f the chamber. After a certain time period, the drug molecular diffused onto the
PBS side was taken by 1 ml pipette and put into quartz cuvette for UV absorbance
measurement. One milliliter o f fresh PBS was then being put back into the chamber for the
diffusion test.

Figure 2.10 Release Chambers (1) 1ml horizontal chamber; (2) magnetic stirrer; (3) chamber
side; (4) 0.2 pm pore size acetate membranes; (5) chamber entrance for drug dispersion
add-in.

CHAPTER 3

TOP-DOWN APPROACH FOR PREPARING
PACLITAXEL NANOCORES

In this chapter the top-down approach is described. Some sections o f this chapter were
published in a paper written by the author o f this dissertation

in co-authorship with Dr.

Lvov and others as “Converting Poorly Soluble M aterials into Stable Aqueous Nanocolloids”
in Langmuir, 2011, 27 (3), 1212-1217. The text sections cited from this paper is properly
cited as [72], and they are not in use in any other dissertation.
Ultrasonication can be applied to create extreme physical-chemical conditions at the
liquid/gas interface, whereas the bulk solution can stay at room-temperature. During
high-power ultrasonication (20 kHz, 50-100 W) gas bubbles are formed and expanded,
followed by cavity implosion and je t formation. This creates very high local tem perature (up
to 5000 K) and high pressure (up to 103 atm) in the center o f the cavity, whereas the bulk
solution remains at low-temperature because o f localized energy release and high cooling rate.
This high pressure and the jet formation crush solid materials into micro- and nanoparticles
[27-31],
In this chapter, the top-down

ultrasonication

approach for preparing paclitaxel

nanocolloid will be discussed as a representative method developed for preparing small size
low soluble drug nanocolloid. The chemical structure o f paclitaxel is shown in Figure 3.1.
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NH

OH

Figure 3.1 Chemical structure for paclitaxel

3.1 T op -D ow n A p p roach
Figure 3.2 shows the scheme for top-down approach. In this process, ultrasonication was
applied to break down crystal structure o f paclitaxel into nanoparticles while they are coated
with polyelectrolyte

to

provide

the

system

colloidal

stability.

Oppositely

charged

polyelectrolytes were applied one layer at a time for the prevention o f recrystallization o f
those nanoparticles.
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Figure 3.2 Scheme for top-down approach [72]
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To be more specific, 0.5 mg/ml o f paclitaxel crystal were added into De-Ionized water,
and then ultrasonication with 15 W/cm" in power was applied for 45 minutes. Due to the
negative surface ^-potential o f the drug particle, polycation (positive polyelectrolyte such as
chitosan, protamine sulfate and polylysine) was added to the solution during ultrasonication
was continuously adsorbed onto the particle surface during the crystal broken down process
providing enhanced surface potential. During this process, ca. 300 nm size drug particles
coated with a layer o f polycation were obtained.
A set o f experiments had been done to figure the minimal amount o f polyelectrolyte
necessary for surface recharging and further Layer-by-Layer shell build up. This minimal
polyelectrolyte amount minimized the non-reacted polyelectrolyte remaining in bulk solution.
Then oppositely charged polyanions (negative polyelectrolyte such as heparin, albumin and
alginic acid) whose surface charge is opposite to the previously coated layer, was added into
the solution with extended 15 minutes ultrasonication. This process o f sequential adsorption
o f oppositely charged polyelectrolytes while preserving ultrasonication was repeated three to
five times for stable nanocapsule formation with desired nano-architecture and functionality.
Compared with the conventional Layer-by-Layer process, we minimized those tedious
processes o f washing and centrifugation to form a washless Layer-by-Layer process. After
the completion o f the Layer-by-Layer coating process, the paclitaxel drug dispersions were
centrifuged at 12,000 rpm for 10 m inutes to remove the excess polyelectrolytes. They were
then washed and re-suspended in De-Ionized water for further experiments. The electrical
surface q-potential and size o f the nanocolloids measurements were performed using
ZetaPlus microelectrophoretic instrument and light scattering machine. These machines
characterized the success (or failure) o f the Layer-by-Layer coating. FESEM and laser
confocal microscopy imaging was applied for morphology characterization.
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3.2 Top-Down Approach with Bubbling Agent

As described in Chapter One, the additions o f chemicals which can produce more gas
microbubbles increase the efficiency of ultrasonication. Figure 3.3 shows the SEM image of
paclitaxel before and after top-down approach. As we can see from Figure 3.3 (a), the
original paclitaxel are several microns in length. In Figure 3.3 (b) and Figure 3.3 (c), after the
process using top-down approach, we were able to get paclitaxel nanoparticles around 300
nm in size. The nanoparticles have the good property o f narrow size distribution. However it
is very difficult to break the particle size down to less than 300 nm in size using the top-down
approach. This difficulty may confine its medical application for the small size requirement.

[ » «rwt

(a)

(b)

(c)

Figure 3.3 SEM image o f paclitaxel before and after top-down approach, (a) Original
paclitaxel; (b-c) Top-down sonication method (paclitaxel/(chitosan/alginic acid) 2 ).

Figure 3.4 confirms the SEM result o f paclitaxel nanoparticles after top-down approach
with bubbling agent using Precision detectors PDExpert light scattering workstation. It shows
that the paclitaxel nanoparticles coated with PAH/PSS had an average size o f 120 ± 30 nm
obtained with LbL ultrasonication enhanced with bubbling agent N H 4H C O 3 used at
concentration 1 mg/ml. This result also shows its narrow particle size distribution.
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Figure 3.4 Light scattering result o f paclitaxel after top-down approach with bubbling agent
(X-axis: size in nm, Y-axis: ratio o f particles o f certain size as compared to the total particles)

Figure 3.5 shows the SEM result for using bubbling agent on large scale. We can clearly
see particle size uniformity (assuming that singe particle circles form these rings).

Figure 3.5 SEM image for paclitaxel nanocores formation with bubbling agent enhancem ent
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3.3 Zeta Potential M onitoring the LbL Process
The best way to monitor the Layer-by-Layer process is to control the reversal change o f
the particle surface potential changing during the process o f alternate adsorption and coating.
As can be seen from Figure 3.6, 2,-potential o f original paclitaxel crystal was found to be
-20mV. Without the Layer-by-Layer coating, initial nanocolloids were stable only during
sonication; however, aggregation came quickly when the power sonication was terminated.
Therefore the Layer-by-Layer coating was applied for better stability. In the first trial for
Layer-by-Layer coating, we applied synthetic polyelectrolytes (polycation: poly (allylamine
hydrochloride) (PAH) and polyanion: poly (styrene sulphonate) (PSS)) since they have higher
ionization and surface charge which help in anchoring on nanocolloids. This synthetic
polyelectrolytes coating process is a common way for Layer-by-Layer study and had been
applied in industry. After the process was elaborated, we began to use biocom patible
polyelectrolytes (polycation: chitosan, polyanion: alginic acid) since for real biomedical
application we need our drug formulation to be biocompatible and biodegradable.

PAH

30

PAH

ft

Chitosan
Chitosarr

Alginic Acid

O. -20
3

-30

Paclitaxel

-40
-50
PSS

PSS

-60

Figure 3.6 2,-potential monitoring o f the Layer-by-Layer process for the nanocolloids for
synthetic and natural biodegradable polyelectrolytes
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Figure 3.6 shows the alternate change in surface ^-potential o f the drug nanoparticles
during the adding o f each polycation and polyanion solution during permanent sonication.
The first polycation layer o f poly (allylamine hydrochloride) (PAH) switched the surface
^-potential to 30 ± 3 mV, higher than that o f biocompatible chitosan at 24 ± 2 mV. The

following first polyanion layer o f poly (styrene sulphonate) (PSS) switched the surface
^-potential back to -47 ± 3 mV, more negative than that o f biocompatible alginic acid at
-35 ±3 mV. Both the adsorption o f polycation and polyanion layer was continued and showed
the regular electrical potential reversal. The changes in potential proved the successful
coating o f Layer-by-Layer technology. And this worked also for both natural biodegradable
polyelectrolytes chitosan and alginic acid.
Figure 3.7 shows the chemical structure for chitosan and alginic acid used. Their
biocompatibility and biodegradability have been helpful in cell experiment and human study.
The successful coating with synthetic and biodegradable polyelectrolytes shows the
versatility o f materials choice for building up the architecture using Layer-by-Layer
technology.

HOCH,

(a) polycation: chitosan

(b) polyanion: alginic acid

Figure 3.7 Chemical structure for biocompatible polyelectrolytes: (a) polycation: chitosan (b)
polyanion: alginic acid

After the three to four bilayers coating with these polyelectrolytes, drug nanocolloids can
be stable for at least one week without essential aggregation (no sediments).
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For biocompatible polyelectrolytes, we also tried com binations o f peptides and proteins
(positive protamine sulfate (PS) and negative bovine serum albumin). The shell m ade o f
chitosan and alginic acid showed better colloidal stability than protamine sulfate and albumin
combination which aggregated in two days. The better stability is due to their higher surface
potential since after the final alginic acid layer coating, the nanoparticle reached the value
more (in magnitude) than -30 ± 3 mV. which is considered as a threshold o f stable colloid
formation. Therefore, the optim ization o f the shell architecture for better stability was
important. This surface ^-potential characterization showed similar result for the sim ilar

architecture shell samples with and without bubbling agent, but bubbling allowed sm aller
initial nanocore formation.

3. 4 Confocal Fluorescence Image
Figure 3.8 shows the confocal fluorescence image for the paclitaxel nanoparticles coated
with PAH and FITC-labeled PSS by top-down approach. We understand that we do not see a
real image o f the particle because it is smaller than the confocal microscope resolution
(500nm). With this image, we ju st want to dem onstrate that our paclitaxel nanocolloid is well
dispersed and non-aggregated (so each separate particle image is smeared due to the
convolution with instrumental function).

J

uki

Figure 3.8 Confocal fluorescence image for top-down approach
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3.5 Efficiency o f Bubbling Agent Method
An important question is: what is the chemical stability o f the samples under high local
spot temperature in oxygen-saturated solutions and with the existence o f bubbling agent? We
needed to prove the final outcome for the bubbling agent method to be not de-com posed
paclitaxel. X-ray diffraction (XRD) had been applied for study o f the crystalline structure o f
the final LbL shelled nanocolloids.
Hypothesis: The bubbling agent added during the process o f sonication will evaporate
and will not have an effect on the composition o f the final outcome, that is, the final outcome
is still paclitaxel.
Methodology: Use XRD to identify crystalline structure o f the final output o f bubbling
agent method with pure paclitaxel and to compare it with crystal structure o f the original bulk
paclitaxel.
Result: The XRD result is shown in Figure 3.9. The XRD measurement is based on
the Bragg's law: 2d sin0=nL For the function, 0, X and d are the scattered angle o f the X-ray,
wavelength o f the X-ray and d-spacing o f the sample resepectively. The d-spacing is the
distance between crystalline planes, which gives information about the sample. The bottom
curve shows the information o f the 20 peaks o f pure paclitaxel. The top curve shows the
information of the

2 0

peaks o f final outcome o f bubbling agent method. It can be clearly seen

from Figure 3.9 that the peaks o f the two samples overlap well with each other. According to
the Bragg's law, they have the same d-spacing, which gives information about the sample.
The overlap means that the final outcome o f the bubbling agent method is paclitaxel.
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2-Tbeta - Scate

Figure 3.9 The XRD results o f pure paclitaxel (bottom curve) and the final outcome o f
bubbling agent method (top curve)

Conclusion: The bubbling agent added during the process o f sonication does not have
any essential effect on the composition o f the final outcome. The final outcome is still
paclitaxel.

3.6 Mechanism o f Bubbling Agent for Enhancement
o f Ultrasonication Capability
To maximize the ultrasonication capability for nanoparticulation, the bubble nucleation
rate is a key parameter. Using N H 4H C O 3 as a bubbling agent to enhance bubble nucleation
allowed us decreasing size o f colloid particles closer to 100 nm (Figure 3.3(d)). To be
specific in experiment, N H 4H CO3 had been dissoled in the first polycation solution and then
added into the drug solution during sonication. This bubbling agent was completely
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decomposed and "bubbled-out” during sonication as NH3 and
distribution diagram was centered at

1 2 0

CCT gases. The size

nm and its width is 60 nm.

Figure 3.10 shows the result for top-down method with bubbling agent. Its average size is
120 ± 30 nm. It is much smaller than without bubbling agent.

Figure 3.10 SEM image o f paclitaxel coated with PAH/PSS with average size o f 120 ± 30 nm
obtained with top-down LbL ultrasonication enhanced with bubbling agent N H 4H C O 3 used at
concentration 1 mg/ml [72],

Besides the gas concentration in solvent, the bubble nucleation rate dN/dt depends on gas
concentration, temperature, surface tension, pressure, hydrophobicity o f the substrate surface
[30]:
dN/dt = Constant * c * exp(-AE/kT).
Here c is gas concentration, AE =
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uo3 P' 2 g(0)/3

(Eq. 1)

is the energy barrier for the bubble

nucleation, T is the surrounding temperature, a is the liquid/air surface tension. P is pressure;
0

is the contact angle o f the surface.
Since we used an aqueous medium for the nanocolloid synthesis, there was a minute

variation for surface tension and contact angle as compared to possible pressure variation
(additional two to three atm may essentially increase ultrasonication efficiency). Therefore,
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higher gas concentration through bubbling agents increases nucleation. An increase in
pressure will decrease the energy barrier, also resulting in the increase o f bubble nucleation,
and is thus helpful for the nanoparticle formation. It was found that low wettability of
materials (which is the case for more hydrophobic low soluble materials) formed the shape of
a bubble resulting jet flow directing to the particle surface which may increase explosion
energy [31].
Though the nanoparticulation procedure is reliable, there are number o f features which
have to be discussed and clarified in future studies:
1) The role o f adsorbed polyelectrolytes may be
re-charging but may also serve as cleaving

not only in the particle surface

agents, filling and widening m icrocracks

caused by sonication. Dependence o f the procedure on molecular weight o f the used
polyelectrolytes may be important.
2) In all our experiments, electrical surface potential (^-potential) o f micro/nano particles
after ultrasonication (but before polyelectrolyte deposition) was negative. It may be due to
partial oxidation o f the particle surface under ultrasonication. This assumption has to be
checked and control over the depth o f such oxidation may require operations in nitrogen
atmosphere.
3) Even increasing ultrasonication power and extending its time did not allow smaller
particle sizes:

2 0 0

-nm diameter was a kind o f “m agic” barrier for many o f our colloidal

particles. We suggested that diameter barrier may be related to the nucleation size o f vapor
bubbles. This assumption allowed us to decrease colloid particles to 150 nm diam eter using
agents enhancing bubbling formation (such as NH 4 HCO 3 ). The process o f the bubble
nucleation related with materials hydrophobicity has to be analyzed to get even smaller
particle sizes.
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3.7 Conclusions
Paclitaxel nanoparticles LbL coated by biodegradable (chitosan/alginic acid ) 3 shells were
produced with the size in the range o f 150-200 nm. Bubbling agents allowed higher
ultrasonication power for smaller paclitaxel nanocores formation. These nanocolloids were
stable for at least one week in water at concentrations o f 0.5 mg/ml and pH 6.5. In Chapter
Four, we will describe another drug nano-core formulation which helped us to avoid titanium
dioxide contamination.

CHAPTER 4

B O T T O M -U P A P P R O A C H F O R D R U G N A N O F O R M U L A T IO N

There are two approaches applied in our study. One is top-down approach with powerful
ultrasonication as discussed in the previous chapter. In this approach, we used paclitaxel as a
representative low soluble drug and obtained good results with LbL encapsulation o f ca 150
nm diam eter nanoparticles. However, a large obstacle o f this method was a necessity o f long
ca one hour high power ultrasonication which resulted in TiOi nanoparticle detachment from
the titanium electrode and contamination o f the sample. Mice injection even was possible but
unsafe for small animals.
The other approach is the bottom-up approach with the surfactants such as lipids,
Polysorbate 80 (TW EEN 80), or albumin possessing some amphiphilic properties. We
applied this approach for paclitaxel and lapatinib nanocores formation accomplished with
LbL encapsulation. In this approach, a low soluble drug was dissolved in a good solvent
(ethanol) for dissolution into molecular solution and then desolvation process (water addition
initiating crystallization) with permanent sonication and addition was applied. Amphiphile
molecules were added to the mixture to arrest drug nucleation and to provide charged sites
for anchoring o f the fist polycation layer coating. This approach was quite different from the
top-down approach in the kinetics o f the nanoparticle formation (nanocrystal growth from
molecular solution) rather than from breaking down bigger crystals. Some sections o f this
chapter were published in a paper written by the author o f this dissertation in co-authorship
with Dr. Lvov and others as “Top-down and Bottom-up Approaches in Production of
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Aqueous Nanocolloids o f Low Solubility Drug Paclitaxel”, in Physical Chem istry Chemical
Physics, 2011,13, 9014-9019. The text sections cited from this paper is properly cited as [73],
and they are not in use in any other dissertation.

4.1 Bottom-Up Approach with Powerful Ultrasonication
4.1.1 Method Description
Figure 4.1 shows the scheme for bottom-up approach with powerful ultrasonication. In
this process, a low soluble drug was dissolved in a good solvent (ethanol or acetone).
Powerful ultrasonication was then applied with amphiphilic Polysorbate 80 and aqueous
polycations were slowly added into the drug solution. Water was additionally added into the
solution to decrease the solubility o f the drug in the solution. With the increment o f water
volume in the drug solution and evaporation o f solvent, solubility o f the chosen drugs
decreased. The solution would then reach saturation and nucleation would begin to form drug
nanoparticles. The combination o f powerful ultrasonication and amphiphiles stopped those
nanoparticles from growing into bigger particles (“arrested” nucleation). As discussed earlier
in similarity to the top-down approach, oppositely charged polyelectrolytes were then
sequentially adsorbed onto the surface o f drug nanoparticle to help form a high surface
charge layer to provide further colloidal stability for drug particles. After 30 minutes o f usual
sonication treatment (not using very high power but rather usual sonication bath),
centrifugation at

1 2 , 0 0 0

rotates per minute for

1 0

minutes were applied to precipitate these

drug crystals already pre-coated with Polysorbate 80 and one polycation layer. They were
then re-suspended in De-Ionized water. A second layer o f polyelectrolyte (anionic) was
deposited to further enhance the drug particle surface c,-potential (recharging it to negative).
Unreacted polyelectrolytes were removed by centrifugation and Layer-by-Layer drug
nanoparticles with size around 150 nm were obtained both for paclitaxel and lapatinib.
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Further Layer-by-Layer polyelectrolyte was applied for these stabilized nanocolloids for
building

up

needed

shell

architecture

using

traditional

process

without

powerful

ultrasonication.
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Figure 4.1 Scheme for bottom-up approach with powerful ultrasonication

Figure 4.2 shows the test result o f temperature o f the solution during ultrasonicaion and
the evaporation rate o f Di-Ionized (DI) water, 60% Ethanol/De-Ionized water mixture and
pure ethanol. As we can see, the evaporation rate o f ethanol during powerful ultrasonication
was close to that o f being heated to 80 °C. Therefore, the temperature in the ultrasonication
solution was very close to 80 °C. The evaporation rate o f De-Ionized water was much smaller
than ethanol and that o f 60% ethanol/De-Ionized water mixture is in between them. Typically,
our disolvation process took 25-30 minutes.
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Figure 4.2 Evaporation rate of different solution during sonication

4.1.2 Optimization Process
Here we would like to show our process o f optimization for getting better smaller size
drug nanoparticles. Our optimization process included the following parameters: solvent type,
concentration, used amphiphile molecules, water instillation speed, original paclitaxel or
lapatinib concentration, sonication time and the application o f centrifugation. They are
discussed in detail below:
1. Solvent ty pe: ethanol VS acetone.
Figure 4.3 shows the effect o f different organic solvent on final drug particle size.
Paclitaxel (4 mg) in 2 ml ethanol or acetone solvent was sonicated. Then 100 ul 2 mg/ml o f
poly (allylamine hydrochloride) (PAH) solution was added in, and 2 ml o f De-lonized water
was slowly added into the solution. As can be seen, the solvent ethanol gives better
dispersion and less aggregation result for drug nanoparticles than acetone.
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(b) acetone

Figure 4.3 SEM image o f final drug nanoparticles by different solvent type

2. Effect o f concentration.
Figure 4.4 shows the effect o f solvent concentration (0%, 30%, 60%, 90%) on the final
nanoparticle size. Paclitaxel (4 mg) in 2 ml ethanol solution (0%, 30%, 60%, 90%) was
sonicated. Then 100 ul 2mg/ml o f poly (allylamine hydrochloride) (PAP!) solution was added
in, and 2 ml o f DI water was slowly added into the solution. As we can see, 60%
ethanol/De-Ionized water mixture gives nest dispersion and particle size.
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Figure 4.4 SEM image o f final drug nanoparticles by different ethanol concentration

3. W ater instillation speed.
Figure 4.5 shows the effect o f DI water addition speed on particle size. With the
increment o f addition speed, particle size grows bigger. This effect can be explained by the
fact that with the increment o f addition speed, the solubility decreases faster leading to faster
crystal nucleation rate and the possibility o f aggregation gets higher leading to the increment
in the final drug particle size. The low DI water addition speed at 0.5 ml/min allowed the
drug molecule to form crystals slowly and protected and stabilized by polyelectrolytes with
smallest size.
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Figure 4.5 Effect o f DI add in speed on particle size [73]
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4. Drug concentration.
As one can see from Figure 4.6, with the increment in the initial drug concentration, the
aggregation tendency during nucleation process increased leading the final particle size
getting larger.
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Figure 4.6 Effect o f drug (paclitaxel) initial concentration on particle size [73]

5. Sonication time.
With the increment o f sonication time (Figure 4.7), the drug particle size decreased. After
45 minutes, there is no big change in particle size. Therefore, in our study, 45 minutes o f
ultrasonication w'ere usually applied for the coating o f first polyelectrolyte layer.
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Figure 4.7 Effect o f sonication time on paclitaxel particle size

6. Centrifugation.
In our approach, we still had some larger particles at the edge o f the container which
would be harmful. Therefore, centrifugation was been applied for removing bigger particles.
The result can be seen in Figure 4.8.

■
H llljH lih f i

(a) before centrifugation

(b) after centrifugation

Figure 4.8 Centrifugations to eliminate bigger particles

Figure 4.9 shows the increment o f centrifuge speed and time decreases the final particle
size to a certain extent. Our optimization result was choosing 2000 rpm and 10 minutes as the
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premium speed and time, since too high centrifuge speed and too long at a time will cost the
loss of drug concentration.
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Figure 4.9 Effect o f (a) centrifuge speed (r/min) and (b) time in minutes (2000 r/min) on the
paclitaxel particle size (the y-axis, in nanometers)

4.1.3 Bottom-up Method with Bubbling Agent Enhancement
With the optimized process above, we then applied the bubbling agent to the bottom-up
approach. The procedure for bottom-up method with bubbling agent is described below:
1)

Dissolve 0.5 mg/ml o f drug in 20 ml 60% Ethaol/De-Ionized water solution and start

ultrasonication for five minutes; 2) Add in polycation and bubbling agent solution (1 mg/ml)
and further apply ultrasonication for 45 minutes; 3) Slowly add in DI water during sonication,
The solubility o f the drug will decrease and crystallization will be initiated but being kept
from growing into larger particle with sonication and polyelectrolyte coating; 4) Bottom-up
method with bubbling agent will produce drugs with 30 nm in size; 5) Polycation coating of
nanoparticles provides colloidal stability and allow further LbL shell formation.
The result for bottom-up method with bubbling agent enhanced method is shown in
Figure 4.10. Some very small drug particles with the sized around 30-40 nm in size are
available.
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Figure 4.10 Bottom-up method with bubbling agent (images from different part o f the
paclitaxel sample)

4.1.4 Bottom-up Approach with Magnetic Particle Milling
Preparation: 1) 0.5 mg/ml Pac in 20 ml 60% Ethanol/Di water. Sonicate for five minutes.
2) Add in 2/0.5/1 mg/mg/ml PAH/ Fe 3 CVDI 3ml drop by drop in three minutes. 3) Add in
0.5/0.125/1 mg/mg/ml PAH/FesCVDI 20 ml using syringe for 45 minutes. Notes: Fe 3 C>4 was
not completely dissolved in DI. Take upper liquid for experiment. 4) Take the sample after
sonication, centrifugation, filtration, and centrifugation plus filtration samples, denoted as 1,
2, 3 and 4 for SEM.
Figure 4.11 shows the SEM image o f bottom-up method with magnetic particles for
sample 3 after filtration. We can see many 20 nm particles on the edges , which could be

Fe 3 C>4 after sonication. Drug particles around 200 nm in size were obtained. For the sample
after centrifugation and filtration process in Figure 4.12, we still see some drug surrounded
by Fe 3 C>4 , but the concentration may not be high enough. This process can be further studied
and improved.

(a) edge o f the sample

(b) center o f the sample

Figure 4.11 SEM image o f bottom-up method with magnetic particles
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Figure 4.12 SEM sample of magnetic particle coating on the drug after centrifugation and
filtration process

4.2 Bottom-up with Surfactants Assisted Sonication Approach
Another bottom-up approach applied in our research is using those surfactants such as
albumin, polysorbate 80 (TWEEN 80) and polyvinylpyrrolidone (PVP) during sonication.
We applied this approach for paclitaxel and lapatinib. In this approach, we use a regular
sonicator rather than a powerful ultrasonicator. Since the samples prepared by powerful
ultrasonicator usually has black precipitate o f TiCT which polluted of the drug nanocapsules.
It is difficult to remove them because they have close particle sizes. Therefore, we used
regular sonication and combined our LbL approach with traditional emulsification process
with addition o f biodegradable surfactants to anchor polyelectrolytes on the surface o f the

62

formed drug nanoparticles. This chapter is mostly devoted to our second anticancer drug at
work: lapatinib. Chapter Six o f this dissertation will show, for the first time, the combined
action o f these two drugs assembled within one LbL nanocapsule.
Figure 4.13 shows the chemical structure o f lapatinib. It is a drug with very low solubility.
It is widely used as an orally active drug for breast cancer.

(a) Chemical structure o f lapatinib

(b) Chemical modeling structure o f lapatinib

Figure 4.13 Lapatinib structural formulas

Let us give a brief introduction o f the surfactants used in this study. The chemical
structure o f polysorbate 80 (TW EEN 80) and polyvinylpyrrolidone (PVP) are shown in
Figure 4.14. Polysorbate 80(TWEEN 80) is an emulsifier and nonionic surfactant.lt is a
viscous and soluble yellow liquid widely used in the food industry. It is derivative ofoleic
acid and polyethoxylated sorbitan. Its hydrophilic polyethers groups (polyoxyethylene groups)
are biocompatible. Polyvinylpyrrolidone (PVP) is a water-soluble polymer. It is polymerized
from its monomer N-vinylpyrrolidone.
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(a) Polysorbate 80 (TWEEN 80)
Figure 4.14 Polysorbate 80 and polyvinylpyrrolidone

(b) Polyvinylpyrrolidone (PVP)
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For this approach, a small amount o f albumin and polyvinylpyrrolidone was added into
PBS (Phosphate buffered saline) buffer solution and then regular sonication was applied. A
low soluble drug was dissolved in a good solvent (DMSO) for dissolution into molecule and
then added into the surfactant solution during sonication. Biocompatible polyelectrolyte
PLB16-5 (PEG and PLL (Polylysine) block copolymer PLL [16kDa]-b-PEG [5kDa] as
shown in Figure 4.15) was added for LbL coating.
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Figure 4.15 PLL -block-PEG (PLB)

4.3 Conclusions
In this chapter, we described LbL nanoencapsulation of another anticancer drug: lapatinib.
In Chapter Seven we will demonstrate LbL assembly o f paclitaxel and lapatinib in one LbL
capsule.

C H A PTER 5

CAPSULE PEGYLATION AND CONTROLLED RELEASE
STUDY FOR LAPATINIB AND PACLITAXEL

5.1 PE G ylation
5.1.1 PE G ylation Process
To overcom e difficulties with drug nanoform ulation colloidal stability in high m olarity PBS
(Phosphate Buffered Saline) buffer, w e developed LbL shells w ith PE G ylation. For this w e used
block copolym er o f cationic PLL with PEG. N o essential changes in the LbL deposition m ethod
w ere necessary. The detailed procedure for PEG ylaed shell assem bly is shown below :
1) Tw o point five m icroliters o f PB S, 10 pi 60 m g/m l o f album in/PB S, 50 pi o f PV P

(80

m g/m l) added together and sonicate for tw o m inutes.
2) D uring sonication, add 200 pi lapatinib/D M SO (7 m g/m l), keep sonication for 20 m inutes.
3) U sing around 20 pi PLB (PEG and polylysine block copolym er) (60 m g/m l in acidic
PBS), 20 pi heparin (60 m g/m l in acidic PB S) for layer by layer coating by sonicating for one
m inute each tim e.
4) T aking h a lf m ililiter sam ple, centrifuge at 2,000 rpm for 10 m inutes, and keep the
supernatant, w e get nanoparticles 150 nm in size.
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5) Centrifuging the above supernatant at 10,000 rpm for

1 0

minutes, get the bottom

sample, sonicate and add in the same amount o f PBS, and get particle size at 125 nm as
shown in Figure 5.1.

09

95% R=125nm

0.7

0.5

0.3

0.1

Figure 5.1 Lapatinib particle size after PEGylation (X-axis: size in nm, Y-axis: ratio of
particles o f certain size as compared to the total particles)

6

) The steps three to five were repeated to make 3.5 bilayers on top o f the drug particles

with heparin being the outmost layer. Drug particles around 180 nm in size, -36 pv in surface
charge were obtained. Figure 5.2 shows the SEM image for lapatinib nanoparticles with 3.5
bilayers o f PLB (polyethylene glycol and polylysine block copolymer) and heparin.

Figure 5.2 SEM image for lapatinib nanoparticles after Layer-by-Layer coating; the shell
composition is as follows: lapatinib/albumin/ (PLB 16-5/heparin) 3 5
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5.1.2 Monitoring o f the Assembly Process with PEGvlation
The relationship between zeta potential and the amount o f polyelectrolyte (PE) volume
has been shown in Figure 5.3. The initial zeta potential for drug particle without any
PLB16-5 (PEG and PLL (Polylysine) block copolym er PLL [16kDa]-b-PEG [5kDa]) coating
is around -36 ± 2 mV with albumin coating as the outer layer. With the addition o f PLB
(Polyethylene glycol (PEG) solution, the zeta potential increased gradually to around
38 ± 2 mV, and with the addition o f negative polyelectrolyte heparin, the zeta potential
decreased gradually to around -39 ± 2 mV. The amount o f heparin used was a little bit larger
than that o f PLB (Polyethylene glycol (PEG) solution. This process can be repeated as shown
in Figure

5.3. This method allowed researchers to avoid the intermediate sample

centrifugation because due to step-wise polycation/polyanion addition, we were able to find
the point of complete particle recharging and switched to the oppositely

charged

polyelectrolyte.
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Figure 5.3 Zeta potential (y-axis, unit: mV) VS Polyelectrolyte (PE) volume (X-axis, unit: ul).
Zeta potential monitoring o f lapatinib drug during coating, at each point at the graph we
added 0.02 mL polyelectrolytes (first cationic, then anionic, and further again cationic and
anionic, following the particle recharging process), the shell composition is as follows:
lapatinib/albumin/ (PLB 16-5/heparin)2
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5.2 Controlled Release Study
5.2.1 Concentration Study and Productivity o f Our Method
In our study, we want to figure the productivity o f our drug o f the Layer-by-Layer coating.
The most common method for detection the concentration is to use UV spectroscopy for the
calibration and testament o f the concentration o f the drug. The calibration curve for lapatinib
in DMSO is shown in Figure 5.4. The result was applied for the study o f concentration of
lapatinib in the solution.

y = 52.483x + 0.0966
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Figure 5.4 UV calibration result for lapatinib in DM SO (concentration mg/ml)

The initial lapatinib nanoparticle concentration is 0.45 mg/ml. After the Layer-by-Layer
coating, final centrifugation at 12000 rpm for 10 minutes, and remove the upper liquid,
re-disperse in same amount o f PBS, the nanoparticle concentration is 0.25 mg/ml, which is
around 56% o f productivity.
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5.2.2 Release Test for Lapatinib in PBS Buffer
Lapatinib release study in 80 mg/ml PBS-TW80:
Add 0.05 ml nano-lapatinib into 2 ml 80 mg/ml PBS TW 80, test its UV absorbance. It is
used as the total concentration for release in UV test.
Add 0.05 ml nano-lapatinib into 150 ml PBS-TW 80 for release test. Each time take 2 ml
for UV tests.
Draw the release curve according to the Absorbance data as shown in Figure 5.5.
The release time for 97.4% release is, therefore, four hours, and the release equation is a
log equation: y=0.27351n(x)-0.512. And the confidence o f this release curve is R2=0.9264.
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Figure 5.5 Lapatinib nanocapsule release study in 80 mg/ml PBS-TW80

5.2.3 Release o f Drug from Different Formulation (Effect o f LbL Shell)
This section was published in a paper written by the author o f this dissertation

in

co-authorship with Dr. Lvov and others as “Top-down and Bottom-up Approaches in
Production o f Aqueous Nanocolloids o f Low Solublility Drug Paclitaxel,” in Physical

69

Chemistry Chemical Physics, 2011, 13, 9014-9019. The text section cited from this paper is
properly cited as [73], and they are not in use in any other dissertation.
The release profiles o f original paclitaxel powder, paclitaxel nanocolloids with one
polycation layer and three polycation/polyanion bilayer coating were analyzed in standard
sink conditions (initial drug concentration was 2 mg/ml). The release curves fitting were done
with exponential Peppas’ model. Seventy percent o f original paclitaxel powder was released
within eight hours (Figure 5.6).

100

-

80

2

40
♦ Nano paclitaxel
original paclitaxel
10

▲ paclitaxel-(PAH/BSA)2

Figure 5.6 Release from paclitaxel nanocolloidal particles produced with SLbL top-down
approach: PAH coating-1, original paclitaxel without coating-2, and (PAH/BSA)3 coating-3
[73].

Nanoparticulated paclitaxel coated with one polyelectrolyte layer lead to slightly faster
release due to smaller particle size in nanoformulation as compared with m icrometer size o f
the original paclitaxel. Paclitaxel nanocolloids coated with three bilayers o f PAH / BSA
showed lower drug release rate due to increasing thickness o f the capsule wall. For example,
in eight hours only 40% o f the two layers coated sample was released as compared with 80%
for one layer coated sample. LbL technique allows for control o f drug release rate from
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polyelectrolytes-stabilized nanoparticles by changes the number o f coating layers or the shell
composition.
Under sink conditions, 50% o f non-coated paclitaxel crystals (without sonication) were
solubilized within two hours, while three LbL coating bilayers extended this time to more
than ten hours (extrapolation). Similar release rate results were obtained for bottom-up
approach in paclitaxel nanoparticulation. Paclitaxel coated with one layer o f PAH after
bottom-up approach (particle size was 100 ± 20 nm) showed slightly faster release than
top-down approach (particle size is 220 ± 20 nm) due to the sm aller particle size.
Conclusions:

In the proposed paclitaxel and

lapatinib formulation, we obtained

150-200 nm drug particles, but our nanocapsules contained high drug content o f 80-90% due
to very thin capsule walls (o f ca 10 nm, as it was estimated from Quartz Crystal
M icrobalance measurements o f the LbL multilayers o f corresponding compositions). The
drug release time from LbL capsules was found to be between 10 and 20 hours depending on
the shell thickness.
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CHAPTER 6
D U A L D R U G S E N C A P SU L A T IO N O F
PA C L IT A X E L A N D LA PA T IN IB

In this chapter, the preparation and characterization o f dual drug paclitaxel and lapatinib
is

shown.

In

a

multidrug-resistant

(MDR)

ovarian

cancer

cell

line,

OVCAR-3,

paclitaxel/lapatinib nanocolloids mediated an enhanced cell growth inhibition in comparison
with the paclitaxel-only treatment. A series o f in vitro cell assays were used to test the
efficacy o f these formulations. The small size and functional versatility o f these nanoparticles,
combined with their ability to incorporate various drugs, indicated that paclitaxel/lapatinib
nanocolloids may have in vivo therapeutic applications. Some sections o f this chapter were
published in a paper written by the author o f this dissertation

as “ Lapatinib/Paclitaxel

Polyelectrolyte Nanocapsules for Overcoming M ultidrug Resistance in Ovarian Cancer,” in
Nanomedicine: Nanotechnology, Biology, and M edicine (2011 Nov 16) [74].
Figure 6.1 shows how the drug particles are formulated (basically based on the former
sonication

assisted

Layer-by-Layer

approach)

and

the

in

vivo

toxicity

test

of

paclitaxel/lapatinib colloidal nanoparticles. It will be discussed in detail in the following
sections o f this chapter.

72

I. Fnrniation ot colloidal n .tin ■par licit--

II. I n Miro Invicitv of Pacliiavcl ' I.apatinih co.lnidal n a iin p a rlic k '

Figure 6.1 Formulation and in vivo toxicity test o f paclitaxel/lapatinib colloidal nanoparticles
[74] (The bottom left picture: red dots: lapatinib. black dots: paclitaxel. The bottom right
picture is shown in Figure 6.9)

6.1 In trod u ction
Ovarian cancer is one o f the most common gynaecological m alignancies in women and
the leading cause o f gynaecological cancer-related deaths in dev eloping countries [76]. This
mortality rate is due to the lack o f early symptoms for ovarian cancer that becomes clinically
evident until it reaches an advanced stage. The picture is com plicated by the failure o f the
current available therapies that are not very effective. The m ajor obstacle is the presence o f
several mechanisms o f drug resistance, some o f which have been well described, for many o f
the currently chemotherapies used for the treatment o f ovarian cancer including paclitaxel
[77]. Paclitaxel is a drug o f natural origin isolated from the bark of Taxusbrevifolia [78] and
currently used for the treatment o f ovarian cancer and breast cancer. Paclitaxel promotes
microtubule assembly and stability, an effect that results in the disruption o f the normal
microtubule network required for mitosis.
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Efforts have been made over the past years to overcome drug resistance associated with
paclitaxel treatment and a number o f specific factors have been identified as causes o f
paclitaxel resistance; however, the underlying complex mechanisms are far from fully
understood.

Paclitaxel

resistance

has

been

associated

with

the

overexpression

of

P-glycoprotein, altered expression o f specific tubulin isotypes, activation o f the Toll-like
receptor (TLR)-M yD88 signaling pathway and H IF-lalpha stimulation by hypoxia [79-83],
Furthermore, paclitaxel presents a poor solubility in water and it is formulated for its
current clinical administration in a mixture o f Cremophor EL/absolute ethanol (50% v/v).
This preparation has been associated with several side effects including nephrotoxicity and
neurotoxicity [84].
To overcome toxicity, to increase bioavailability and to control drug release, several
approaches for packing paclitaxel are under investigation. Since 2005, albumin-based
nanoparticles were approved by the US Food and Drug Administration and, during these
years, new nanoparticle formulations, such as polymeric nanoparticles, micelles, dendrimers
and liposomes, demonstrated to possess numerous benefits over conventional methods and
early nanoparticles products [85-88],
Among the wide panel of novel formulations under investigation, previous studies have
shown that Layer-by-Layer nanoassembly technique can be used efficiently for the
nano-encapsulation o f poorly soluble anti-cancer drugs [72].
In particular, stable nanocolloids o f paclitaxel were prepared by sonication assisted
Layer-by-Layer (SLbL) self assembly technology. Under powerful ultrasonication, the
air-bubble dissolved in water underwent the formation and implosion o f cavity, followed by
the jet flow and thus extreme physico-chemical environment was created. Drug crystals were
broken into smaller and smaller particles. During this process, polyelectrolyte o f opposite
charge to the drug was added and absorbed onto the drug crystals through electrostatic forces:
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this helps for preventing aggregation o f the newly formed nanoparticles. Since the
ultrasonication is based on the collapse o f air-bubbles, a bubbling agent such as N H 4 H C O 3
was mixed with the polyelectrolyte to increase the intensity o f ultrasonication [72], By this
method, drug nanoparticles around 150 ± 50 nm in size were achieved. Generally speaking,
initial drug particles are negative in charge. After the first polyelectrolyte coating (in this case,
polycation), the surface potential becomes positive. Then a second layer polyelectrolyte (in
this case, polyanion), was coated and the surface charge reversed back to negative. This
surface charge reversal can be repeated several tim es to demonstrate the successful coating o f
different polyelectrolyte layers which can build up such architecture and maintain properties
such as controlled release by tailoring layers composition and number. The Layer-by-Layer
self assembly technology can also be applied for combining two drugs in one nanocolloid
system for enhancing synergistically drug efficiency [73].
For all these reasons, we hypothesized that paclitaxel clinical efficacy can be increased
through a strategy that combines improvements in paclitaxel cellular delivery and
combination o f targeted therapies to inhibit one or more signalling pathways involved in
paclitaxel resistance. O f all these mechanisms o f drug resistance, overexpression o f
P-glycoprotein (P-gp), a member o f the ATP-binding cassette (ABC) transporters [89], has
been associated with a poor response to chemotherapy [90]; therefore, its impairment is likely
to have a significant impact on paclitaxel clinical action. However, until now, many P-gp
inhibitors failed during pre-clinical and clinical studies [91]. Recently, lapatinib, an epidermal
growth factor receptor (EGFR) and Erb-2 dual tyrosine kinase inhibitor have been shown to
inhibit the function o f ABC transporters including P-gp [92],
In this work, the efficacy o f paclitaxel-Ioaded nanocolloid formulations has been tested
in two ovarian cancer cell lines in vitro compared to that o f paclitaxel given alone.
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Furthermore, a co-therapv strategy which results from the combination o f paclitaxel and
lapatinib in nanocolloids showed to be very effective in enhancing paclitaxel efficacy.
Overall, results o f this study showed that paclitaxel-nanocolloids increased antitum or
efficacy o f paclitaxel and that the combination with lapatinib, can significantly overcome
multidrug resistance in ovarian cancer cell lines. These results are encouraging for the
development o f multifunctional nanocolloids that could be used in the clinical practice.

6.2 Methods
6.2.1 P re p ara tio n o f N an o co llo id s
To build up the nanocapsules for a simultaneous controlled release o f two drugs, we used
a SLBL technique. Biodegradable chitosan (polycation) and alginic acid (polyanion) were
chosen for a biocompatible and biodegradable coating on drug NPs.
A Heilscher UIP lOOOhd Ultrasonicator (Germany) was applied at its maximum power
(15 WcnT2) to break the drug colloid into smaller nanoparticles. Water/ ice mixture was used
for the cooling o f the beaker with drug particles under the powerful ultraasonicatior to
prevent overheating and oxidation o f the drug.
1) Paclitaxel samples.
Paclitaxel (40 mg), chitosan (6 mg) (M W =2500) and N H 4 H C O 3 (40 mg) were added to
30 ml De-Ionized (DI) water, stirred for Five minutes and then sonicated in water/ice bath for
45 minutes (to make paclitaxel/chitosan). After 45 minutes, six ml alginic acid solution (one
mg/ml) was added in during sonication; sonicated for 25 minutes (to make paclitaxel
/chitosan/ alginic acid).
The

coating

process

o f chitosan

and

alginic

acid

were

repeated

to

make

(paclitaxel/chitosan/alginic acid/chitosan/alginic acid /chitosan/alginic acid) nanocolloid.
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2)

Paclitaxel/lapatinib dual drug nanocolloids preparation: (paclitaxel/chitosan/alginic

acid/chitosan/lapatinib/chitosan/alginic acid).
Paclitaxel (40 mg), chitosan (6 mg) and N H 4 H C O 3 (40 mg) were added in 30 ml
De-lonized (Dl) water, stirred for five minutes and then sonicated in water/ice bath for 45
minutes (to make paclitaxel/chitosan complex). After 45 minutes, 6 ml alginic acid solution
(1 mg/ml) was added during sonication for 25 minutes (to make paclitaxel/chitosan/alginic
acid). Six milliliter o f 1 mg/ml chitosan solution was added, and then sonicated for 25
minutes (to make paclitaxel/chitosan/alginic acid/chitosan). Lapatinib solution (20 ml, 0.5
mg/ml) was added for sonication for 25 minutes (to make paclitaxel/chitosan/alginic
acid/chitosan/lapatinib). Chitosan (6 ml, 1mg/ml) solution was added under sonication for 25
minutes

(to

produce

paclitaxel/chitosan/alginic

acid/chitosan/lapatinib/chitosan).

Six

milliliter o f AA solution (in 1 mg/ml concentration) was added, and then sonicated for 25
minutes (to make paclitaxel/chitosan/alginic acid/chitosan/lapatinib/chitosan/alginic acid).
Samples were centrifuged at 2000 rpm for 20 minutes to remove lower solid. The samples
were then centrifuged at 10000 rpm for 10 minutes to remove upper liquid.
6.2.2 C ell V iability A ssay
Cells were seeded at a density o f 5 x 103 per well in a 96-well plate containing 100 pi o f
full medium and allowed to adhere to the plate overnight. For determining cell viability, the
MTT assay was used. After treatment with paclitaxel or LbL-paclitaxel nanocolloids for
24 hours, the culture medium was aspirated and 100 pi o f fresh medium containing 10 pi o f
MTT solution (stock five mg/ml in PBS) was added to each well. Cells were then incubated
for further two to three hours. After removal o f MTT solution, 100 pi o f DMSO were added
to the wells maintained in agitation for 15 minutes. Absorbance of the converted dye was
measured at a wavelength of 570 nm with background subtraction at 690 nm. The relative
cell viability was expressed as a percentage o f the untreated control wells.
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6.2.3 R everse T ranscription-P C R
Total

cellular

RNA was

isolated

by

IllustratriplePrep

extraction

kit

following

m anufacter’s instruction and immediately used. Purified DNA and protein pellets were stored
at -80° C for further analysis.
Reverse transcription polymerase chain reaction was then performed by using the High
Capacity RNA-to-cDNA M aster Mix (Applied Biosystem). Approximately one pg o f total
RNA was converted to cDNA.
PCR was conducted on a MyCycIer thermal cycler (Bio-Rad). The final volume o f 25 pi
included one pi o f cDNA template, 12.5 pi o f PCR M aster M ix (Promega), and one pi o f a
mix containing primers.
The primers used for PCR amplification were designed using the Prim er blast program
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and were as follows: Cofilin sense 5’
GTGGGCGATGTGGGCCAGAC 3 ’, antisense 5’ CCAGGGTGCAGCGGTCCTTG 3 ’ (280
base pairs, bp, Tm 60°); Cyclin D1 sense 5’ CGCTTCCTGTCGCTGGAGCC 3 ’, antisense 5 ’
CTTCTCGGCCGTCAGGGGA

3’

(111

bp,

Tm

60°);

GAPDH

sense

5’

GCATGGCCTTCCGTGTCCCC 3’, antisense 5’ CAATGCCAGCCCCAGCGTCA 3 ’ (216
bp, Tm 60°).
PCR was carried out using the following conditions: denaturation at 95 °C for 30 s,
annealing at 60 °C for 30 s, and extension at 72 °C for 45 s. PCR samples were loaded onto a
1.2 % agarose gel containing ethidium bromide and analysed. All PCR experiments were run
in triplicate. GAPDH was used as an internal loading control.
6.2.4 Im m u n o b lo ttin g A ssay
Proteins were extracted in RIPA buffer (50 mM Tris-base, 150 mM NaCl, 0.1% SDS, 1%
Triton X-100, 0.5% sodium deoxycholate, one mM sodium orthovanadate, 10 mM sodium
fluoride, 1% protease inhibitor cocktail) and lysates were clarified by centrifugation at
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13000 g for 15 minutes at 4°C. Protein concentration was determined using the Bradford
protein assay. Proteins (50 pg) were separated on 10% polyacrylammide gel and transferred
to nitrocellulose membranes (Amersham Biosciences). The membranes were blocked
overnight in 5% non-fat milk in TBST buffer (Tris Buffer Saline and 0.1 % Tween 20) at 4°C
under agitation, and subsequently probed by the appropriately diluted primary antibodies in
blocking buffer. The blots were then incubated with HRP-conjugated secondare antibody for
two

hours

at

room

temperature.

Target

proteins

were

detected

by

enhanced

chemiluminescence reagents and visualized on Hyperfilm ECL films (Amersham).
6.2.5 C onfocal M icroscopy
Exponentially growing ovarian cancer cells were seeded on 25 mm square glass cover
slips placed in 35 mm diameter culture dishes. After treatment, cells were fixed for five
minutes with 3.7% formaldehyde in phosphate-buffered saline (PBS) solution, permeabilized
with a 0.1% solution o f Triton X-100 in PBS, and incubated for 30 minutes at room
temperature with phalloidin-TRITC (Sigma) (one pgfnl in PBS from one m gfnl DM SO stock
solution). After that, cells were washed three times in PBS. The preparations were mounted
in 50% glycerol in PBS. Images were acquired by laser confocal microscopy using a TCS
SP5 (Leica Microsystem GmbH, M annheim, Germany).
6.2.6 S tatistical A nalysis
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad Software, San
Diego, CA, USA). Differences between group means were compared by Student's t-test.
Student’s t-test was used for the statistical analysis o f RT-PCR and western blot data. Data
are presented as mean ± standard error o f the mean (s.e.m.). A probability level o f P < 0.05
was considered significant.
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6.3 Results
The aim o f this study is to develop new strategies based on nanocolloids technology to
overcome multiple drug resistance (M DR) associated with paclitaxel in ovarian cancer.
Preliminary experiments were performed to identify cellular targets o f paclitaxel action. The
identification o f these targets will be useful as m arkers o f nanocolloids action respect to
paclitaxel alone.
An ovarian cancer cell line, OVCAR-3, was chosen for its drug-resistance phenotype and
used as model system in this study. The M DR phenotype o f this cell line was confirmed by
the presence at mRNA level o f TLR4 and P-glycoprotein (P-gp) (Figure 6.2 E), which were
associated with paclitaxel chemoresistance [79, 81-82]. The expression levels o f these
mRNA. MDR1 mRNA is greatly expressed in OVCAR-3 with respect to M CF-7 while no
significant differences were observed for TLR-4.
The over-expression o f the glycoprotein P-gp, a member of the ATP-binding cassette
(ABC) protein family, has profound implications in the clinical practice. In fact, the presence
o f drug efflux pumps that mediate the active efflux o f chemotheraputics is one o f the most
extensively described mechanisms o f drug resistance and strategies to m odulate or blocking
this process that have been investigated actively in oncology [93], In ovarian cancer, P-gp
overexpression at the mRNA and protein level has been implicated in chem oresistance,
correlated inversely with patient survival and associated with resistance to paclitaxel [94-96],
Dose-response studies highlighted the resistant nature o f this cell line (Figure 6.2 B).
Exponentially growing OVCAR-3 cells were exposed to increasing concentration o f
paclitaxel (from 1.5 ng/ ml to 5000 ng/ ml) for 24 hours and MTT cell viability assay was
performed. As shown in Figure 6.2, the cancer cell line exhibited a characteristic
dose-response curve, in fact, treatment with paclitaxel at concentration above 10 ng/ml did
not induce a proportional reduction of cell viability.

80

CTR

PTX 5ug/ml

24h

A)

MTT test (% control)

120

100-

80
60
40
20 -

O

1.5

5

10

25

50

75

150

300

625 1250 2500 5000

PTX c o n c e n tra tio n ng/m L

B)

□
■
8

60-

CTR PTX

C)

10x104

CTR PTX

CTR PTX

CTR PTX

8x104

6x104

4x104

CTR
PTX

81

h e u lc ij

OTfc

0

CT*
15 m in

Ins***)
1 h

C 'lH

lw .* d

I.'TB

1 h

CAM
24 h

CTR

—

—

- —

1
1

—

_ _

treated

pAKTser473

AKT2

AK T I

AKT1

AKT 2

GAPDH

TUB

D)
OVCAR-3

MCT-7

MDR1
TLR4
GAPDH

Figure 6.2 Paclitaxel inhibits cell growth o f OVCAR-3 cells
A) Evaluation o f the effects o f paclitaxel on OVCAR-3 cell morphology using phase-contrast
microscopy after 24 hours o f incubation (magnification 10 x). Cell death was observed
after paclitaxel treatment as evidenced by the increasing number o f floating cells. B)
Paclitaxel reduces cell viability. OVCAR-3 were seeded overnight into 24-well plates and
incubated with paclitaxel at the indicated concentrations. After 24 hours, cell viability was
detected by MTT test. OVCAR-3 demonstrated a plateau in survival at concentrations o f
paclitaxel above 5 ng/ml. Values are mean +/- s.e.m. o f three independent experiments
performed in triplicate. C) Paclitaxel reduces cell viability. OVCAR-3 were seeded overnight
into 24-well plates at the indicated concentrations and incubated with paclitaxel for 24 hours
at 5 pg/ml. The response of OVCAR-3 to paclitaxel is independent o f the number o f cell
seeded. Values are mean +/- s.e.m. o f three independent experiments performed in triplicate.
D) Paclitaxel reduces Akt phosphorylation at ser 473. OVCAR-3 cells were cultered in
DMEM m edia supplemented with 10% FBS for 24 hours followed by starvation for 12 hours
in serum-free media. Cells were switched to the media in the absence (CTR) or presence
(treated) o f paclitaxel 5 pg/ ml for 15 minutes, 1 hour, 4 hours and 24 hours, respectively.
The whole cell lysates were prepared, and western blotting was performed as described in the
Materials and Methods. Blots were stripped and re-probed with total Akt isoforms. The level
o f tubulin was used to indicate relative amounts o f protein loaded. Experiments were
performed three times and blot is a representative o f one independent experiment. (Right)
paclitaxel effects on the expression o f Akt 1, Akt 2. RT-PCR showed mRNA levels o f Akt
isoforms after paclitaxel treatment. The expression o f GAPDH is shown as internal control.
E) Expression o f MDR1 and TLR4 measured by RT-PCR in untreated OVCAR-3 and MCF-7
cells. The expression o f GAPDH is shown as internal control.
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Comparable findings were obtained in a similar experiment, in which the drug
concentration was maintained fixed and the num ber o f cell seeded on the plate was changed
(Figure 6.2 C). Ovarian cancer cells seeded at four different concentrations and treated with
paclitaxel at 5 ng/ ml for 24 hours showed a sim ilar survival ratio between control and treated
cells. This result means that cytotoxicity due to paclitaxel in less dependent on the
concentration o f the drug at concentrations above 10 ng/ml. In the case o f OVCAR-3, the
1C50 could not be determined because even at concentrations o f paclitaxel upper than 20
ng/ml more than 50% o f the cells remained viable (data not shown). In contrast, an IC50 o f
100-200 ng/ml has been determined by MTT (data not shown) for MCF-7 (drug sensitive)
cells suggesting that the multidrug resistance transporter MDR-1 is associated with resistance
to paclitaxel in OVCAR-3.
In recent years, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway has risen to
prominence as a regulator o f cell survival and growth in many different cell types. In ovarian
cancer, constitutive Akt activity or gene amplification was frequently detected in tumor
samples and associated with chemoresistance and poor prognosis [97, 98]. Akt promotes cell
survival and growth through a variety o f mechanisms, including the regulation of
proapoptotic proteins Bad and caspase-9 and cyclin D1 expression [97],
To determine the effects o f paclitaxel on this signaling pathway, an experiment of
western blot was conducted to investigate the phosphorylation status o f Akt ser 473 after
paclitaxel treatment. Ovarian cancer cell lines were grown under normal conditions and were
deprived o f serum overnight. Cells were then treated or not (control) with paclitaxel in
presence o f serum. Western blot analysis showed that levels o f pAkt ser 473 were reduced
compared to those in control cells that, on the contrary, increase when stimulated with serum
at the indicated times (Figure 6.2 D).
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No differences were noted in the levels o f total Akt 1 and Akt 2 isoforms at both mRNA
and protein levels, suggesting that paclitaxel-regulation of this pathway results largely from
post-transcriptional regulation.
To investigate whether the encapsulation o f paclitaxel in nanocolloids leads to a general
improvement o f the efficacy o f the drug, we assayed the cytotoxicity o f the LbL-paclitaxel
toward the OVCAR-3 cell line and compared the results with that of paclitaxel free.
To assess this point, two types o f LbL-nanocolloids were fabricated and tested:
paclitaxel-chitosan and paclitaxel-chitosan-alginic acid. In particular, chitosan is a positively
charged natural carbohydrate polymer with minimal toxicity that shows strong electrostatic
interaction with the negatively charged mucosal surface [98], Chitosan has been largely used
as biomaterials and the much higher expression o f mucin, heavily glycosylated extracellular
protein, in ovarian tumors compared to the surrounding normal tissue [99] can provide a
rationale for using chitosan as delivery system in ovarian tumors. Both preparations were
tested on ovarian cancer cells for their ability to increase paclitaxel efficacy. The results
obtained by M TT test were comparable for the two types o f nanocolloids, and for this reason,
we will use the general name o f LbL-paclitaxel nanocolloids to design both formulations. As
shown in Figure 6.3, paclitaxel and LbL-paclitaxel have a similar trend o f cytotoxicity in
ovarian cells with a higher cytotoxicity for LbL-paclitaxel than paclitaxel alone. It should be
noted that, since cells incubated for 24 hours with empty LbL-nanocolloids (drug free) does
not shown any significant difference in cell viability compared to control cells. We exclude a
role of empty nanocolloids to explain the difference between paclitaxel and LbL-paclitaxel.
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Figure 6.3 Citotoxic effect o f LbL-paclitaxel nanocolloids on OVCAR-3 and SKOV-3 cancer
cells and regulation o f pAkt ser 473 and cyclin D1 expression

Citotoxic effect o f paclitaxel alone or LbL-paclitaxel nanocolloids at the indicated
concentrations was measured by the M TT assay as described in Section 6.2. Control cells
were treated with paclitaxel free or paclitaxel-LbL nanocolloids. Values are mean +/- s.e.m.
o f three independent experiments performed in triplicate. The cell viability is related to
control wells treated with vehicle (DMSO) or empty LbL-nanocolloids (drug free).
Regulation o f pAkt ser 473 and cyclin D1 by paclitaxel or LbL-paclitaxel nanocolloids:
Ovarian cancer cells were treated with paclitaxel or LbL-paclitaxel nanocolloids at the
concentration o f 1.5 ng/ml for 24 hours. Whole cell lysates (50 pg in each lane) were
subsequently subjected to western blotting analysis with antibodies to pAkt ser 473 and
cyclin D l. RT-PCR analysis o f cyclin D1 mRNA expression levels was performed as
described in Section 6.2.
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Moreover, we observed that the treatment o f ovarian cancer cells with LbL-paclitaxel
results in cell growth inhibition at the concentration o f 1.5 ng/ml where the same
concentration o f paclitaxel free does not affect cell viability.
Comparison of ovarian cancer cells treated with LbL-paclitaxel and paclitaxel at the
concentration o f 1.5 ng/ml revealed a down-regulation o f pAkt ser 473 only for LbLpaclitaxel treated cells. Akt pathway is known to play a pivotal role in the regulation o f cyclin
D1 expression in ovarian cancer cells [100], Therefore, we examined if paclitaxel or
LbL-paclitaxel nanocolloids regulate cyclin D1 expression. After 24 hours o f treatm ent at the
concentration o f 1.5 ng/ ml only LbL-paclitaxel nanocolloids were able to decrease cyclin D1
protein level. Cyclin D1 mRNA level remains unaffected after treatment suggesting the
regulation at the protein level.
We next determined if increased LbL-paclitaxel nanocolloids cytotoxicity respect to
paclitaxel free could be explained by a higher down-regulation o f the Akt pathway. Western
blot analysis o f pAkt ser 473 from ovarian cells treated with paclitaxel and LbL-paclitaxel
nanocolloids at five pg/ml showed a significant difference in the pospho-protein level in
control with respect to treated cells with a further down-regulation in LbL-paclitaxel treated
samples (Figure 6.3 B), a finding that correlates with the increased cytotoxicity o f
nanocolloids compared to paclitaxel free.
The enhanced cytotoxicity o f drug-nanoparticles could be explained considering the
different mechanisms o f drug-nanocolloids uptake compared to paclitaxel free. Several
mechanisms have been described including the increased accumulation o f the nanoparticles
in the cells and their entrapment in the endosomes/lysosomes rendering the drug inaccessible
for P-gp [101].
A possible link between the activation o f PI3K/Akt pathway and actin rem odeling has
been described [102-103]. It has been shown that PI3K/Akt pathway induced cell migration
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through the remodeling o f actin filaments and that actin is a cellular target o f this kinase
[104-105]. It is possible that the involvem ent o f this pathway in paclitaxel action could have
consequences

on

the

organization

o f actin

cytoskeleton

after

paclitaxel

treatment.

TRITC-phalloidin staining o f F-actin followed by confocal microscopy analysis revealed
some differences in the cell shape and organization o f actin filaments for paclitaxel free and
LbL-paclitaxel cells compared to control (Figure 6.4 A). Not treated cells show regular
shaped bodies, with a readily visible actin staining in the periphery, actin profusions (yellow
arrows. Figure 6.4 A) and the absence o f bundles o f actin filaments. Rounded cells appeared
after paclitaxel treatment together with the formation of blebs (green arrows. Figure 6.4 A).
No actin profusions are more v isible in treated cells. Furthermore, a more distinct net o f actin
filaments is visible in the cytoplasm o f OVCAR-3 treated with LbL-paclitaxel nanocolloids.

PTX treated

p C O F ser 3

COP

C O Fm RN A

Figure 6.4 Effects o f paclitaxel or LbL-paclitaxel nanocolloids on actin cytoskeleton:
(A) Ovarian cancer cells plated on glass coverslips were treated with paclitaxel or
LbL-paclitaxel nanocolloids at the concentration o f 5 pg/ ml for 24 hours and then fixed.
Cells were stained with TRITC-phalloidin. (B) The phosphorylation status o f cofilin at ser 3
was assessed with a phoshospecifie antibody, and then the blot was reprobed for total cofilin
levels. The mRNA level o f cofilin was assessed by using a specific set o f primer.

I he organization o f actin filaments is gov erned by a plethora o f proteins that regulate the
rate o f actin polymerization. One o f the key proteins in this scenario is cofilin. which can
regulate the rate o f actin-filament turnover and the net polymerization o f actin. In particular.
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actin dynamics is regulated by phosphorylation o f cofilin at serine, which renders
phospho-cofilin

inactive towards

F-actin

[106],

We examined by

western

blot the

phosphorylation status o f cofilin after paclitaxel or LbL-paclitaxel nanocolloids treatment. As
shown in Figure 6.4 B, cofilin phosphorylation increased after paclitaxel treatm ent and, in
particular, after the exposure with LbL-paclitaxel. This result is consistent with the
morphological actin-changes observed by confocal microscopy and raises questions about the
role o f the actin cytoskeleton in mediating paclitaxel sensitivity. Moreover, the significant
effect o f LbL-nanoparticles on cofilin phosphorylation will prompt us to investigate the role
o f actin cytoskeleton in mediating the uptake the LbL-nanoparticles into OVCAR-3 cells.
In summary, the Akt pathway is a target o f paclitaxel and LbL-paclitaxel action; the
modulation o f this pathway after paclitaxel treatm ent can affect the cell growth as observed
by MTT.
Moreover, LbL-paclitaxel nanocolloids lower the mininum dose necessary to obtain a
significative reduction o f cell viability an issue that can be important for future possible
application in vivo in order to minimize the cytotoxicity and adverse side effects associated
with paclitaxel. On the other hand, although the cell growth inhibition o f paclitaxel free and
LbL-paclitaxel nanocolloids reached a statistical difference, nanocolloids did not produce a
sustained

growth

inhibition

in ovarian

cancer cells suggesting that

LbL-paclitaxel

nanocolloids are susceptible to efflux by P-gp. Thus, the combination with an interrelated
drug is required to optimize the therapeutic activity o f nanoparticle-encapsulated drug.
In search for novel strategies to overcome resistance o f ovarian tumor cells, we tested the
cytotoxic activity o f paclitaxel in combination with two small molecule chemical inhibitors,
U 0126, an extracellular signal-regulated kinase (ERK) 1/2 inhibitor, and LY29004, a PI3K
inhibitor. Both signal-pathways have been described and well characterized for their role in
drug-resistance [97, 107],
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In addition, the combination with lapatinib, an inhibitor o f the intracellular tyrosine
kinase domains o f both the EGFR and Her-2 receptors, was further explored to increase the
cytotoxic efficacy o f paclitaxel. The combination o f lapatinib with paclitaxel has been
explored in the clinical practice. In fact, clinical trials demonstrated the efficacy o f lapatinib
and paclitaxel in HER-2-positive locally advanced or metastatic breast cancer [103],
Moreover, the ability o f lapatinib to reverse multidrug resistance due to ABCB1 and ABCG2
transporters, including P-gp, has been recently described with the potential to increase the
cytotoxic effects o f several chemotherapeutic drugs including paclitaxel [108]. This finding
supports the idea to combine paclitaxel and lapatinib in our cell line that shows a high
expression o f P-gp. As shown in Figure 6.5, an improvement o f paclitaxel efficacy is
obtained when the drug is administrated in combination with the ERK 1/2 inhibitor U 0126,
suggesting that this pathway may play a role in the generation o f paclitaxel resistance, and a
greatly enhanced of paclitaxel efficacy is obtained in combination with lapatinib. On the
contrary, there are no significant differences in cell viability between cells treated with
LY29004 alone or with LY29004 plus paclitaxel suggesting that LY29004 alone is the major
determinant o f the observed decrease in cell viability.
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Figure 6.5 MTT test was used to test the efficacy o f paclitaxel in combination with the ERK
1/2 inhibitor U 0126, the PI3K inhibitor LY29004 and the drug lapatinib. M TT test was
performed as described in Materials and Methods. Ovarian cancer cells were grown on
96-well plates and treated for 24 hours at the following concentration o f chemicals: paclitaxel
5 pg/ml, U 0126 and LY29004 at 10 pM and lapatinib at 5 pM and 10 pM . Values are mean
+/- s.e.m. o f three independent experiments performed in triplicate

Next, we determined if the therapeutic potential o f LbL-paclitaxel nanocolloids could be
further increased by the co-delivery o f paclitaxel and lapatinib. For this purpose, nanocolloids
containing paclitaxel and lapatinib were prepared by LbL-technology. As shown in Figure.
6.6, the particle size o f paclitaxel with one layer coating was 125 ± 50 nm, much smaller as
compared with several micrometers o f original paclitaxel powder. We monitored the
Layer-by-Layer coating process using the zeta potential analyzer (Figure 6.8 (a)), light
scattering machine (Figure 6.8 (b)) and SEM (Figure 6.7). These results show that the
consequrative coating process had been successful. After Layer-by-Layer coating with
biocompatible and biodegradable layers o f chitosan, alginic acid and lapatinib, the particle
diameter was around 250 nm. Such architectural nanocapsules allowed dual delivery o f these
two drugs.
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Figure 6.6 SEM images o f paclitaxel (a) and lapatinib (b) before treatment. Ultrasonication
assisted coating o f first layer on paclitaxel: (c) Sonicator, (d) SEM image, (e) Light scattering
result

Figure 6.7 SEM image o f Layer-by-Layer coating o f paclitaxel nanoparticles: (a)
paclitaxel-(chitosan-alginic acid ) 3 and (b)paclitaxel-(chitosan-alginic acid) 3 -laptinib-alginic
acid
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Figure 6.8 Layer-by-Layer coating o f paclitaxel nanoparticles: (a) Zeta-potential and (b)
Diameter as a function o f coated layers

Results obtained by MTT test confirmed the enhanced cytotoxic activity o f this
nanopreparation compared to paclitaxel free and LbL-paclitaxel (Figure 6.9).
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Figure 6.9 LbL-paclitaxel/lapatinib nanocolloids demonstrate significant cytotoxic
activity in P-gp overexpressing ovarian cancer cells as determined by M TT test. Values are
mean +/- s.e.m. o f three independent experiments performed in triplicate (p<0.05 *; p<0.01
**; p<0.001 ***).

6.4 Discussion
Ovarian cancer still remains one o f the most fatal malignancies among women.
Improving the efficacy o f current therapeutics will have a great impact in the m anagement o f
the disease. Paclitaxel is widely used for the treatm ent of patients with ovarian cancer, but
despite substantial clinical efficacy the optimal administration regimen remains elusive.
Many questions remain concerning the way to administer the drug and the molecular
mechanisms at the basis o f chemoresistance.
Among the proteins related to the chemoresistance process, the overexpression o f P-gp
has profound implications in clinical practice. In fact, the presence of drug-efflux pumps that
mediate the active efflux o f chemotherapeutics is one o f the most extensively described
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mechanisms o f drug resistance, and strategies to modulate or block this process have been
investigated actively in oncology [111]. In ovarian cancer, the expression o f P-gp has been
implicated in chemoresistance, correlated inversely with patient survival and associated with
resistance to paclitaxel [102-114],
These observations set the stage for the developm ent o f efficacious instruments to
increase paclitaxel efficacy by limiting adverse side effects and increasing its cytotoxic action.
In this regard, nanotechnology has been recognized as a fundamental tool in cancer research
[115] and the potential o f nanocarriers to increase drug efficacy is well described [116-118].

6.5 Conclusions
Here, we describe a SLbL method to efficiently convert paclitaxel into drug NPs. It
allows clinicians to combine many necessary factors for an efficient drug-delivery system: i)
control of nanocolloid size within 100-300 nm, ii) high drug content o f approxim ately 70%
wt, iii) shell biocompatibility and biodegradability, and iv) sustained controlled release.
Overall, these characteristics, including the small size and the net negative charge, that can be
advantageous for their penetration to and within tumors, make NPs attractive candidates for
possible in vivo applications.
In addition, in this research we elaborated nanoformulation o f two drugs in one
nanocapsule locating paclitaxel in the core and lapatinib on the shell periphery. The rationale
for considering combination therapy is to overcom e major problems associated with
paclitaxel administration, such as the counteraction o f paclitaxel resistance and, in
combination with dose-escalation, the potential reduction o f systemic toxicities. Moreover,
with this strategy both drugs can be temporally co-localized in the tum or cells for optimal
synergy, limiting possible differences in the pharmacokinetics and tumor accum ulation o f the
two different agents.
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Given the molecular complexity o f cancer, drug combinations are most likely to translate
into a significant clinical benefit. To further increase the therapeutic potential o f nanocapsules,
a research objective that remains to be explored regards the realization o f a target delivery
system. Surface functionalization by targeting ligands or antibodies is an attractive
opportunity to direct NPs toward cancer-specific cells or tumor-specific clones with
substantially greater selectivity in tumor killing versus toxicity to normal host tissues. Several
types o f targeting ligands should be used for this purpose, including peptides and antibodies.
These ligands enable NPs to bind specific receptors and to be internalized by endocytosis,
enhancing the intracellular accumulation o f drugs. The feasibility of the LbL method makes
easy the realization o f functionalized NPs by using polymers with free reactive groups for the
outer layer o f LbL NPs. On the contrary, a relevant concern is the identification o f reliable
ligands to impart a precise biological function to NPs. Significant research efforts have been
made in a recent study from the National Cancer Institute Pilot Project for the acceleration o f
translational research, where 75 possible tumor antigens were recognized [119]. Some o f
these tumor-associated antigens, including MUC1, CA

125, NY-ESO-1, and human

epidermal GFR 2 (HER2)/neu are potential targets in ovarian cancer. In particular, due to its
role in cellular transformation and tumorigenieity, MUC1 received great attention in those
years. Recently, a monoclonal antibody anti-M U Cl has been utilized alone or in combination
with docetaxel (DTX) in preclinical models o f ovarian cancer, leading to a significant
increase in survival. Furthermore, a MUC1 aptamer-guided nanoscale drug-deliverysystem
was developed to enhance the paclitaxel delivery to MUC1- overexpressing MCF-7 cells in
vitro [120-121],
To characterize the clinical potential o f nanocolloids loaded with paclitaxel and lapatinib,
preclinical studies in animal tumor models are necessary, including a detailed evaluation of
pharmacokinetics and pharmacodynamics and active intracellular intracellular delivery of
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LbL nanocolloids after intravenous or intraperitoneal administration. Extensive future
research is warranted. Because many women experience recurrences during ovarian cancer
therapy due to drug-resistance mechanisms, we postulate that our approach aim ing at limiting
this problem may serve the purpose o f improving the treatment o f ovarian tumors.

CHAPTER 7

C O N C L U S IO N S A N D F U T U R E W O R K

7.1 C onclusions
In this dissertation, the application o f ultrasonication assisted Layer-by-Layer technology
for the preparation o f multifunctional nanoparticulated forms o f poorly water-soluble
anticancer drugs paclitaxel and lapatinib had been developed. Powerful ultra-sonication
performed in the presence o f surface-active bubbling agents resulted in form ation o f small
drug nanoparticles o f desired size. To stabilize them, the Layer-by-Layer self-assembly o f
multilayer films was built up with properties tailored by controlling the m olecular m akeup
and arrangement with nanoscale precise film thickness. In this process, the nano-architectural
approach designing layers o f different components, including ones serving as diffusion
barrier and outermost layers charging, were realized.
Two different approaches with powerful ultrasonication, top-down approach (sonicating
bulk drug crystals in polyelectrolyte solution) and bottom-up approach (sonicating drug in a
water-miscible organic solvent followed by slowly water add-in) had been successfully
applied for the preparation o f the nanoparticles o f paclitaxel and lapatinib, correspondingly.
For the top-down approach, 200 nm diam eter was a kind o f “magic” barrier for colloidal
particles prepared. We suggested that it may be related to the nucleation size o f the solvent
vapor microbubbles. This assumption allowed us to decrease paclitaxel colloid particles to
120 nm diameter using agents enhancing bubbling formation (such as N H 4 H C O 3 ). However,
a large obstacle o f these powerful ultrasonication methods were a necessity o f long time (one
96
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hour) high power ultrasonication resulted in TiCE nanoparticle detachment from titanium
electrode and contamination o f the sample. Such formed paclitaxel nanoparticles were LbL
coated with 10-20 nm polycation/polyanion shell to provide aqeous colloidal stability and
slower particle dissolution. Mice injection was possible but demanded TiCE purification.
With the bottom-up approach (based on desolvation o f the drug diluted in alcohole), less
powerful sonication was used, and prepared particle sizes of 140-150 nm were obtained both
for lapatinib and paclitaxel. Less sonification time (ca 15 minutes) allowed avoiding TiCE
contamination. Regular sonicatation combined with our LbL approach and traditional
emulsification process with addition o f biodegradable surfactants to anchor polyelectrolytes
on the surface o f the formed drug nanoparticles had been applied to avoid the Ti pollution
created by powerful ultrasonication. The bottom-up approach using polymeric excipients
combined with non-ionic and anionic surfactants along with regular sonication allows
preparing uniform 140-150 nm colloid cores o f lapatinib. The amphiphiles attach to the
hydrophobic nanoparticles and serves as anchors for LbL shell. In contrast to untangled
amphiphiles, LbL polyelectrolyte shells do not detach easily from the surface and retain
integrity upon dilution in another media. The inner LbL layers and surfactants minimize the
surface free energy, thereby preventing crystal form changes and nanoparticles coalescence,
while the outermost layers enhance colloidal stability.
To overcome difficulties with drug nanoformulation colloidal stability in high molarity
PBS buffer, we developed LbL shells with PEGylation for lapatinib. For these shells, we
used block-copolymer o f cationic polylysine with PEG. The best stable in PBS buffer
nanoformulations o f lapatinib have shells consisting o f a block copolymer o f poly-L-lysine
(PLL) and PEG o f different length (PLB) as a positive component o f the shell and heparin as
a negative component. Better colloidal stability o f lapatinib dispersions in PBS was obtained
while using PLB copolymer at every bilayer with the shell architecture o f (PLB/heparin)

3 5

.

98

In the proposed paclitaxel and lapatinib formulation, we obtained 150-200 nm with high
drug content o f 80-90 % due to very thin capsule walls (of ca 10 nm). The drug release time
from the LbL capsules was found to be between 10 and 20 hours depending on the shell
thickness. Washless LbL assembly had been used: 1) addition o f polycation in the amount
that is enough to reverse surface charge o f the dispersion to a high positive (+30 mV) value;
2) addition o f polyanion in the amount that is enough to reverse surface charge o f the
dispersion to a high negative (-30 mV) value. No intermediate washing o f nanoparticles was
done until the shell was complete.
We elaborated nanoformulation o f two drugs in one nanocapsule locating paclitaxel in the
core and lapatinib on the shell periphery. With this formulation o f com bining in one
nanoparticle dual drug we reached the drugs efficiency synergy. In a m ultidrug-resistant
(MDR) ovarian cancer cell line, OVCAR-3, lapatinib/paclitaxel nanocolloids mediated an
enhanced cell growth inhibition in comparison with the paclitaxel-only treatment.

7.2 Future W ork
Upon completion of this research, the following ideas for future work were suggested.
The first idea is the application o f the bubbling agent for the bottom-up approach with regular
ultrasoincaton to get even smaller particle sizes without the pollution o f powerful
ultrasonication. The second idea is trying different encapsulation methods for the preparation
o f dual drugs.
To further increase the therapeutic potential o f nanocapsules, a target delivery system for
anticancer drugs paclitaxel and lapatinib remains to be explored. Surface functionalization by
targeting ligands or antibodies is an attractive opportunity' to direct nanoparticles toward
cancer-specific cells or tumor-specific clones with substantially greater selectivity in tumor
killing versus toxicity to normal host tissues. Several types o f targeting ligands should be
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used for this purpose, including peptides and antibodies. The feasibility o f the LbL method
makes easy the realization o f functionalized nanoparticles by using polymers with free
reactive groups for the outer layer o f LbL shell. Significant research efforts have been made
in a recent study from the National Cancer Institute Pilot Project for the acceleration o f
translational research, where 75 possible tumor antigens were recognized [119-121],
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